<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutrients</journal-id><journal-id journal-id-type="iso-abbrev">Nutrients</journal-id><journal-id journal-id-type="pmc-domain-id">1692</journal-id><journal-id journal-id-type="pmc-domain">nutrients</journal-id><journal-id journal-id-type="publisher-id">nutrients</journal-id><journal-title-group><journal-title>Nutrients</journal-title></journal-title-group><issn pub-type="epub">2072-6643</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12429988</article-id><article-id pub-id-type="pmcid-ver">PMC12429988.1</article-id><article-id pub-id-type="pmcaid">12429988</article-id><article-id pub-id-type="pmcaiid">12429988</article-id><article-id pub-id-type="doi">10.3390/nu17172813</article-id><article-id pub-id-type="publisher-id">nutrients-17-02813</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Amino Acids Supplementation in Cancer: What Do We Feed, the Patient or the Tumor?</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0326-0644</contrib-id><name name-style="western"><surname>Corsetti</surname><given-names initials="G">Giovanni</given-names></name><xref rid="af1-nutrients-17-02813" ref-type="aff">1</xref><xref rid="c1-nutrients-17-02813" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pasini</surname><given-names initials="E">Evasio</given-names></name><xref rid="af1-nutrients-17-02813" ref-type="aff">1</xref><xref rid="af2-nutrients-17-02813" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Romano</surname><given-names initials="C">Claudia</given-names></name><xref rid="af1-nutrients-17-02813" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0445-3106</contrib-id><name name-style="western"><surname>Dioguardi</surname><given-names initials="FS">Francesco S.</given-names></name><xref rid="af3-nutrients-17-02813" ref-type="aff">3</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Bagchi</surname><given-names initials="D">Debasis</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-nutrients-17-02813"><label>1</label>Department of Clinical and Experimental Sciences, University of Brescia, 25128 Brescia, Italy; <email>evpasini@gmail.com</email> (E.P.); <email>cla300482@gmail.com</email> (C.R.)</aff><aff id="af2-nutrients-17-02813"><label>2</label>Institute of Human Health, Ruaha Catholic University, Iringa P.O. Box 774, Tanzania</aff><aff id="af3-nutrients-17-02813"><label>3</label>Nutri-Research s.r.l., 20127 Milan, Italy; <email>fsdioguardi@gmail.com</email></aff><author-notes><corresp id="c1-nutrients-17-02813"><label>*</label>Correspondence: <email>giovanni.corsetti@unibs.it</email>; Tel.: +39-030-0717484</corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>17</volume><issue>17</issue><issue-id pub-id-type="pmc-issue-id">495755</issue-id><elocation-id>2813</elocation-id><history><date date-type="received"><day>21</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>16</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 11:25:14.803"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nutrients-17-02813.pdf"/><abstract><p>Background/Objectives: Diet and obesity contribute to approximately 50% of tumor development. Therefore, nutrition plays a key role not only in cancer prevention but also in determining prognosis. Notably, between 30% and 90% of cancer patients experience malnutrition. Furthermore, the hypercatabolic state induced by tumors leads to widespread protein degradation, clinically manifesting as sarcopenia or cachexia, and ultimately accelerating mortality. This narrative review examines the potential role of amino acids (AAs) in inhibiting tumor growth and counteracting protein&#8211;energy malnutrition&#8212;aiming to preserve muscle mass and nourish healthy cells while placing neoplastic cells in a state of metabolic stress. Methods: The analysis was conducted following the Standards for Reporting Qualitative Research guidelines. Results: Administration of targeted mixtures of essential amino acids (EAAs) has been shown to improve muscle mass, strength, and quality of life in patients with hypercatabolic conditions. Experimental in vitro and in vivo studies also suggest a potential inhibitory effect on tumor proliferation. However, increased availability of certain AAs may, in some cases, stimulate tumor growth, one reason why EAAs supplementation in cancer patients remains controversial. Conclusions: Despite prevailing concerns, emerging evidence indicates that supplementation with a complete, well-balanced EAAs formulation may be a valuable adjunct to standard cancer therapies. This approach could help correct cancer-associated protein imbalances, enhance patients&#8217; quality of life, and create a metabolic environment unfavorable to tumor progression.</p></abstract><kwd-group><kwd>cancer</kwd><kwd>amino acids</kwd><kwd>malnutrition</kwd><kwd>sarcopenia</kwd><kwd>mTOR</kwd><kwd>food integration</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-nutrients-17-02813"><title>1. Introduction</title><p>Cancer is a multifactorial disease influenced by both environmental and genetic determinants. Environmental factors account for approximately 90&#8211;95% of cancer cases, whereas hereditary genetic factors represent a minor proportion. Within environmental determinants, dietary habits contribute to 30&#8211;35% of cases, and obesity to 10&#8211;20%. These two often interrelated factors are therefore responsible for roughly half of all tumor incidences [<xref rid="B1-nutrients-17-02813" ref-type="bibr">1</xref>].</p><p>Nutritional status plays a pivotal role not only in cancer prevention but also in prognosis. A substantial proportion of cancer patients (30&#8211;90%) present with malnutrition, resulting from many different causes as anorexia, reduced caloric intake, taste alterations, malabsorption, impaired digestion, metabolic disturbances, and insufficient food consumption. Moreover, virtually all cancer patients exhibit a hypercatabolic state, leading to systemic and tissue protein degradation. This protein catabolism results in metabolic derangements clinically manifested as sarcopenia, which, if untreated, progresses to cachexia, thereby accelerating mortality [<xref rid="B2-nutrients-17-02813" ref-type="bibr">2</xref>,<xref rid="B3-nutrients-17-02813" ref-type="bibr">3</xref>].</p><p>The risk of malnutrition is particularly high among older adults, with prevalence rates of 45% in community-dwelling individuals, over 50% in hospitalized patients, and 84&#8211;100% in residents of long-term care facilities [<xref rid="B4-nutrients-17-02813" ref-type="bibr">4</xref>]. These conditions further compromise clinical outcomes.</p><p>Clinical evidence demonstrates that administration of balanced mixtures of essential amino acids (EAAs), formulated according to human nutritional requirements, can prevent malnutrition, enhance muscle mass and strength, and improve quality of life in individuals with hypercatabolic conditions such as heart failure and age-related muscle loss [<xref rid="B5-nutrients-17-02813" ref-type="bibr">5</xref>,<xref rid="B6-nutrients-17-02813" ref-type="bibr">6</xref>,<xref rid="B7-nutrients-17-02813" ref-type="bibr">7</xref>,<xref rid="B8-nutrients-17-02813" ref-type="bibr">8</xref>]. Nevertheless, the role of amino acid (AA) metabolism in cancer remains complex and incompletely understood. Indeed, in certain contexts, increased availability of specific AAs may promote tumor growth. Consequently, the use of AAs supplementation in oncology requires careful evaluation.</p><p>This perspective narrative review aims to examine the effects and potential clinical utility of specific AA mixtures in both inhibiting tumor growth and counteracting protein&#8211;energy malnutrition and sarcopenia, with the goal of nourishing healthy tissues while placing neoplastic cells in a state of metabolic disadvantage, drawing on evidence from both experimental and clinical studies.</p><p>To improve the transparency of all aspects of this narrative and qualitative research, we followed the indications proposed by the Standards for Reporting Qualitative Research (SRQR) [<xref rid="B9-nutrients-17-02813" ref-type="bibr">9</xref>].</p></sec><sec id="sec2-nutrients-17-02813"><title>2. Cancer Cell Metabolism: An Overview</title><p>Only recently has it been understood that the metabolic plasticity of the tumor is fundamental to its development and spread. These mechanisms have been brilliantly analyzed in many reviews [<xref rid="B10-nutrients-17-02813" ref-type="bibr">10</xref>,<xref rid="B11-nutrients-17-02813" ref-type="bibr">11</xref>,<xref rid="B12-nutrients-17-02813" ref-type="bibr">12</xref>,<xref rid="B13-nutrients-17-02813" ref-type="bibr">13</xref>]. Therefore, in this paragraph, we will not delve into a detailed discussion but will instead provide a general overview.</p><p>It was Otto Warburg who first observed that tumor cells preferentially use aerobic glycolysis, even in the presence of oxygen, instead of oxidative phosphorylation [<xref rid="B14-nutrients-17-02813" ref-type="bibr">14</xref>,<xref rid="B15-nutrients-17-02813" ref-type="bibr">15</xref>]. The energy yield of the process is much lower than that of the Krebs cycle, but faster [<xref rid="B15-nutrients-17-02813" ref-type="bibr">15</xref>].</p><p>Subsequently, in tumor cells, it was shown that the tricarboxylic acid (TCA) cycle is often &#8220;remodulated&#8221; to produce biosynthetic molecules (such as fatty acids, glucose, nucleosides, and AAs) and to maintain redox balance [<xref rid="B11-nutrients-17-02813" ref-type="bibr">11</xref>,<xref rid="B16-nutrients-17-02813" ref-type="bibr">16</xref>]. AA metabolism is integrated with glycolysis and the TCA cycle to support tumor growth. Indeed, the diversion of 3-phosphoglycerate from glycolysis to serine synthesis provides 1C units for nucleotide synthesis; simultaneously, glycolysis maintains rapid ATP production [<xref rid="B17-nutrients-17-02813" ref-type="bibr">17</xref>]. Furthermore, glutamine supplies &#945;-ketoglutarate (&#945;KG) for TCA; this maintains pools of TCA intermediates that are exported as citrate (cytosolic acetyl-CoA for lipid synthesis) or oxaloacetate for transamination [<xref rid="B18-nutrients-17-02813" ref-type="bibr">18</xref>]. So, a distinguishing feature of tumor cells compared to healthy ones is the upregulation of glycolysis and alterations in the TCA cycle.</p><p>A common feature of all cancers is its growth by parasitizing the host&#8217;s energy and nutrients. It has been observed for a long time that tumors act as &#8220;nitrogen traps&#8221; after comparing the protein metabolism of normal tissue and of tumor tissue [<xref rid="B19-nutrients-17-02813" ref-type="bibr">19</xref>]. It was later observed that tumors utilized plasma proteins more efficiently than free [14C]-leucine. It was therefore concluded that tumor proliferation could be related to the ability of the tumor to trap plasma proteins and use the derived AAs &#8220;starving&#8221; the rest of the organism [<xref rid="B20-nutrients-17-02813" ref-type="bibr">20</xref>]. Subsequent studies have shown that plasma proteins, particularly albumin, are the main source of nutrition for the tumor from which they obtain AAs for their biosynthesis [<xref rid="B21-nutrients-17-02813" ref-type="bibr">21</xref>].</p><p>Today, it is established that the metabolism of cancer cells must be reprogrammed to maintain their survival and proliferation and may even hijack normal cells to create a tumor microenvironment (TME) for tumorigenesis and avoiding immune destruction [<xref rid="B22-nutrients-17-02813" ref-type="bibr">22</xref>].</p><p>In addition to metabolic reprogramming, tumor progression is influenced by multiple factors, including alterations in nutrient utilization, tissue of origin, cellular interactions, and the characteristics of TME [<xref rid="B11-nutrients-17-02813" ref-type="bibr">11</xref>,<xref rid="B13-nutrients-17-02813" ref-type="bibr">13</xref>]. Indeed, EAAs play a dual role in the TME. They are essential for immune cell function but are often co-opted by tumor cells to suppress antitumor immunity through competition, metabolism, and signaling [<xref rid="B23-nutrients-17-02813" ref-type="bibr">23</xref>,<xref rid="B24-nutrients-17-02813" ref-type="bibr">24</xref>,<xref rid="B25-nutrients-17-02813" ref-type="bibr">25</xref>,<xref rid="B26-nutrients-17-02813" ref-type="bibr">26</xref>]. Tumor cells and immunosuppressive cells (e.g., tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs)) express enzymes like arginase 1 (Arg-1) and indoleamine 2,3 dioxygenase (IDO1), depleting arginine and tryptophan in the TME. This inhibits T and NK cell proliferation and function, while promoting regulatory T cell (Treg) expansion and exhaustion through upregulation of the protein named programmed death-1 (PD-1) via the aryl hydrocarbon receptor (AHR) pathway [<xref rid="B24-nutrients-17-02813" ref-type="bibr">24</xref>,<xref rid="B27-nutrients-17-02813" ref-type="bibr">27</xref>]. Therefore, modulating the EAAs metabolism could potentially be useful for promoting effective immune responses against tumor progression.</p><p>Due to the demands of cell growth and the need for newly synthesized molecules, protein biosynthesis is the most energy-demanding process that accounts for about&#8201;33% of total ATP consumption [<xref rid="B28-nutrients-17-02813" ref-type="bibr">28</xref>]. Therefore, mitochondrial activity and metabolism play a critical and fundamental role in promoting tumor proliferation, both by ensuring energy production and by providing essential metabolites for the synthesis of macromolecules and oncometabolites that characterize different types of tumors [<xref rid="B29-nutrients-17-02813" ref-type="bibr">29</xref>].</p><p>Metabolic reprogramming of tumor cells also involves lipids. Lipid desaturation increases the fluidity and flexibility of the cell membrane by facilitating the transport of membrane-associated proteins and lipids, promoting membrane remodeling, aiding cellular plasticity, survival, and migration [<xref rid="B30-nutrients-17-02813" ref-type="bibr">30</xref>,<xref rid="B31-nutrients-17-02813" ref-type="bibr">31</xref>,<xref rid="B32-nutrients-17-02813" ref-type="bibr">32</xref>]. Therefore, tumor cells increase lipogenesis and, to survive, require also a greater modification and high plasticity of lipid metabolism.</p><p>Finally, tumor cells require high availability of AAs, especially non-essential ones, to maintain intense activity [<xref rid="B16-nutrients-17-02813" ref-type="bibr">16</xref>,<xref rid="B33-nutrients-17-02813" ref-type="bibr">33</xref>,<xref rid="B34-nutrients-17-02813" ref-type="bibr">34</xref>,<xref rid="B35-nutrients-17-02813" ref-type="bibr">35</xref>,<xref rid="B36-nutrients-17-02813" ref-type="bibr">36</xref>]; therefore, they also reprogram AAs metabolism [<xref rid="B13-nutrients-17-02813" ref-type="bibr">13</xref>].</p><p>In parallel with the modulation of energy production via glycolysis, tumor cells also modulate numerous biochemical pathways to promote cancer development and spread. In particular, the mammalian/mechanistic target of rapamycin (mTOR) modulation plays an essential role. mTOR is a key cellular regulator that senses nutrients and energy to control growth, metabolism, and survival, with dysregulation linked to diseases like cancer and diabetes. Indeed, it has been identified as the main intracellular target for nutrition-induced cancer development [<xref rid="B37-nutrients-17-02813" ref-type="bibr">37</xref>,<xref rid="B38-nutrients-17-02813" ref-type="bibr">38</xref>]. mTOR is activated by various stimuli such as growth factors, stress, nutrient availability (especially nitrogen), glucose, ATP, and physical activity. In fact, mTOR is at the center of a complex network that controls protein synthesis, cell differentiation, growth, and proliferation [<xref rid="B39-nutrients-17-02813" ref-type="bibr">39</xref>]. Since the mTOR signaling pathway is closely related to tumor metabolism, this provides theoretical support for the combined application of mTOR inhibitors and drugs that interfere with tumor metabolism [<xref rid="B38-nutrients-17-02813" ref-type="bibr">38</xref>]. Other evidence indicates that mTOR activation may have a favorable role in cancer patients. In fact, exercise-induced mTOR activation has been found to be related to the prevention of some types of cancer [<xref rid="B40-nutrients-17-02813" ref-type="bibr">40</xref>,<xref rid="B41-nutrients-17-02813" ref-type="bibr">41</xref>]. Furthermore, mTOR activation can increase the organism&#8217;s tolerability to chemotherapy, inhibit autophagy, and improve prognosis [<xref rid="B42-nutrients-17-02813" ref-type="bibr">42</xref>]. mTOR functions mainly through two complexes named mTORC1 and mTORC2. mTORC1 promotes anabolic processes (protein/lipid synthesis) and inhibits catabolic processes (like autophagy) when nutrients and energy are abundant. mTORC2 regulates cell survival, cytoskeleton organization, and metabolism, especially through Akt (protein kinase B) signaling. Nutrients, especially some AAs, are key stimuli for the regulation and activation of the mTORC1 subunit. In fact, other stimuli are unable to effectively activate mTORC1 when there is a lack of AAs [<xref rid="B43-nutrients-17-02813" ref-type="bibr">43</xref>]. The main specific AAs needed to activate mTORC1 are leucine and glutamine [<xref rid="B44-nutrients-17-02813" ref-type="bibr">44</xref>]. Therefore, AAs can modulate cell metabolism and control cell fate by regulating cell survival and death, and the molecular mechanism is mainly mediated by mTORC1 [<xref rid="B45-nutrients-17-02813" ref-type="bibr">45</xref>].</p><p>In summary, the altered metabolism of tumor cells is not only a key driver of their proliferation, but also a potential Achilles&#8217; heel that can be targeted to counteract them. Emerging evidence indicates that dietary interventions restricting entire nutrient classes&#8212;such as fasting or the limitation of glucose and selected AAs&#8212;can confer anticancer benefits by suppressing tumor progression [<xref rid="B46-nutrients-17-02813" ref-type="bibr">46</xref>].</p></sec><sec id="sec3-nutrients-17-02813"><title>3. The Multiple Roles of Amino Acids in Cancer Cells</title><p>Like any other cells, tumor cells require all AAs to build proteins and proliferate. As previously described, AAs have different and important roles in control of the TME, which is crucial for tumor cell metabolism; therefore, they could be a promising target to inhibit their development and spread [<xref rid="B47-nutrients-17-02813" ref-type="bibr">47</xref>].</p><p>A key question to consider is as follows: do AAs always activate mTORC1, stimulating cell growth and proliferation, favoring anabolism, regardless of their type or molar ratio?</p><p>As is known, AAs can be classified as non-essential (NEAAs) or essential (EAAs), depending on their potential to be synthesized endogenously or not [<xref rid="B48-nutrients-17-02813" ref-type="bibr">48</xref>]. In cancer cells, alterations in AAs metabolism contribute to their metabolic rearrangement and provide the building blocks and energy necessary for proliferation and spread. Historical studies have identified that the main source of AAs used by cancer in tissues that act as reservoirs during prolonged fasting are skeletal muscles and skin [<xref rid="B49-nutrients-17-02813" ref-type="bibr">49</xref>]. It has been known for half a century that 12 AAs are essential for the survival of tumor cells in vitro culture [<xref rid="B50-nutrients-17-02813" ref-type="bibr">50</xref>]. Notably, cancer cells are particularly avid for the NEAAs as glutamine, serine, proline, and glycine, which are most abundant in food proteins [<xref rid="B51-nutrients-17-02813" ref-type="bibr">51</xref>,<xref rid="B52-nutrients-17-02813" ref-type="bibr">52</xref>]. These NEAAs are fundamental for metabolic processes of tumor cells as the synthesis of pyrimidines and membrane lipids, as well as for integrating the Krebs cycle intermediates necessary not only to produce energy but also fundamental to support global cells&#8217; metabolism [<xref rid="B21-nutrients-17-02813" ref-type="bibr">21</xref>].</p><sec id="sec3dot1-nutrients-17-02813"><title>3.1. Glutamine</title><p>Glutamine is a rate-limiting molecule in the cellular reproductive cycle. Indeed, data show that tumor cells generally arrest S phase when deprived of glutamine [<xref rid="B53-nutrients-17-02813" ref-type="bibr">53</xref>]. ASCT2(SLC1A5) is the main glutamine transporter in many cancer cell lines. It is regulated by multiple cancer-associated transcription factors. Therefore, since ASCT2 transports glutamine for cancer cells&#8217; consumption, its inhibition exerts an antitumor action by promoting apoptosis [<xref rid="B16-nutrients-17-02813" ref-type="bibr">16</xref>]. In addition, glutamine also plays a crucial role both for the biosynthesis of proteins, nucleotides, and antioxidant molecules (glutathione), and for energy production in the tricarboxylic acid (TCA) cycle as a precursor of &#945;KG [<xref rid="B16-nutrients-17-02813" ref-type="bibr">16</xref>,<xref rid="B54-nutrients-17-02813" ref-type="bibr">54</xref>,<xref rid="B55-nutrients-17-02813" ref-type="bibr">55</xref>,<xref rid="B56-nutrients-17-02813" ref-type="bibr">56</xref>]. Aerobic oxidation of glutamine provided more than half of the cell energy requirements in HeLa cells and, after substitution of glucose, about 98% of the energy was derived from glutamine [<xref rid="B56-nutrients-17-02813" ref-type="bibr">56</xref>]. So, glutamine is used as a major source of cell energy, rather than for incorporation into proteins.</p><p>Glutamine is metabolized through glutaminolysis, a process catalyzed by glutaminase 1(GLS1) or GLS2 to produce glutamate, and activates mTORC1, regulated by the AMP-activated protein kinase (AMPK)-mTORC1 signaling axis [<xref rid="B16-nutrients-17-02813" ref-type="bibr">16</xref>]. AMPK, a highly conserved serine/threonine kinase complex composed of &#945;, &#946;, and &#947; subunits, acts as a crucial &#8220;fuel gauge&#8221; in eukaryotic cells. It becomes activated when cellular energy is low, signaled by increased AMP/ATP or ADP/ATP ratios, such as during hypoxia, glucose deprivation, or intense muscle activity [<xref rid="B57-nutrients-17-02813" ref-type="bibr">57</xref>].</p><p>The activation of mTORC1 by glutaminolysis during nutritional imbalance led to the anomalous inhibition of autophagy and a subsequent form of apoptosis named glutamminoptosis [<xref rid="B58-nutrients-17-02813" ref-type="bibr">58</xref>]. AMPK activation blocks both glutamine-dependent mTORC1 activation and glutaminoptosis in vitro and in vivo. Furthermore, glutamine is used for asparagine synthesis and GABA shunting to produce ATP and inhibit AMPK, independently of glutaminolysis [<xref rid="B59-nutrients-17-02813" ref-type="bibr">59</xref>]. Asparagine has been identified as an exchange AA factor that regulates mTORC1, nucleotide biosynthesis, and proliferation [<xref rid="B60-nutrients-17-02813" ref-type="bibr">60</xref>]. So, glutamine is sufficient to sustain the production of ATP in the absence of any other AAs, following a glutaminolysis-independent mechanism. The increased uptake and metabolism of GABA in breast to brain metastatic cells was linked to an increase in NADH levels in the microenvironment, conferring a proliferative advantage to the tumor [<xref rid="B61-nutrients-17-02813" ref-type="bibr">61</xref>]. Glutamine metabolism promotes mTORC1 activation through two distinct but parallel pathways: a primary &#945;KG-dependent pathway and a secondary ATP/AMPK-dependent pathway. These pathways regulate the mTORC1-macroautophagy/autophagy pathway [<xref rid="B62-nutrients-17-02813" ref-type="bibr">62</xref>]. The metabolic connection between glutamine and mTORC1 could therefore represent a key point for preventing the growth of tumor cells.</p></sec><sec id="sec3dot2-nutrients-17-02813"><title>3.2. Leucine</title><p>Leucine also acts as an allosteric activator of glutamate dehydrogenase, which is consequently necessary for glutaminolysis induction [<xref rid="B63-nutrients-17-02813" ref-type="bibr">63</xref>]. The addition of glutamine and leucine at similar concentrations in a complete culture medium to AA-starved cells promoted the activation of apoptotic cancer cell death through glutaminolysis-induced activation of mTORC1 via inhibiting autophagy. This highlights that under such conditions, inhibition of mTORC1 results in the survival of cancer cells [<xref rid="B58-nutrients-17-02813" ref-type="bibr">58</xref>]. In addition, previous reports showed that increasing intracellular &#945;KG levels also induces cancer cell apoptosis in vivo [<xref rid="B64-nutrients-17-02813" ref-type="bibr">64</xref>].</p><p>As previously described, short-term glutaminolysis activates mTORC1. In contrast, long-term activation of glutaminolysis, or its end-product &#945;KG, maintains mTORC1 activity for at least 72 h, favoring the activation of apoptosis [<xref rid="B59-nutrients-17-02813" ref-type="bibr">59</xref>]. In AA deficiency, mTORC1 inhibition promoted cell survival. Considering that mTORC1 is hyperactivated in approximately 80% of solid tumors [<xref rid="B65-nutrients-17-02813" ref-type="bibr">65</xref>], and that the TME is frequently nutrient-deprived, sustained mTORC1 activity under nutrient-limited conditions imposes substantial metabolic stress on tumor cells [<xref rid="B66-nutrients-17-02813" ref-type="bibr">66</xref>]. Indeed, glutaminolysis-mediated activation of mTORC1 inhibited autophagy, a process crucial for the survival of the cells upon nutrient deprivation. In contrast, mTORC1 inhibition facilitates epithelial&#8211;mesenchymal transition, thereby enhancing cancer cell migration [<xref rid="B67-nutrients-17-02813" ref-type="bibr">67</xref>].</p><p>Leucine has opposing effects on tumor cells, acting both as a promoter and inhibitor of proliferation. It promotes tumor growth by activating the mTORC1 signaling pathway, which enhances protein synthesis, lipogenesis, and cell proliferation in cancers such as hepatocellular carcinoma, breast, pancreatic, and colorectal cancers [<xref rid="B36-nutrients-17-02813" ref-type="bibr">36</xref>,<xref rid="B68-nutrients-17-02813" ref-type="bibr">68</xref>]. It has been proven that 5% leucine supplementation in mouse pancreatic cancer models increased tumor growth [<xref rid="B69-nutrients-17-02813" ref-type="bibr">69</xref>]. In addition, in bone sarcomas, leucine metabolism supports energy metabolism and tumor survival [<xref rid="B70-nutrients-17-02813" ref-type="bibr">70</xref>].</p><p>On the contrary, leucine supplementation suppresses tumor growth or supports antitumor responses, inducing tumor cell apoptosis and oxidative stress by shifting metabolism toward oxidative phosphorylation. Furthermore, it inhibits the IGF-1/PI3K/Akt/mTORC1 axis and increases levels of the tumor-suppressor p53. In addition, it enhances antitumor immunity by inhibiting regulatory T cells and reducing immune checkpoints like PD-1; it can also compete with kynurenine in the tumor microenvironment, supporting T cell and NK cell function [<xref rid="B16-nutrients-17-02813" ref-type="bibr">16</xref>]. In hepatocellular carcinoma cell lines, combining leucine supplementation with epigenetic therapy (e.g., histone deacetylase inhibitors) led to anti-proliferative effects, decreasing IGF-1 and p70 S6K, while increasing p53 and caspase-3 activity [<xref rid="B71-nutrients-17-02813" ref-type="bibr">71</xref>]. In summary, anti- or pro-tumorigenic effects of leucine supplementation in various cancers should be further investigated to achieve clear conclusions. The dual effects of leucine on tumor progression are schematized in <xref rid="nutrients-17-02813-f001" ref-type="fig">Figure 1</xref>.</p></sec><sec id="sec3dot3-nutrients-17-02813"><title>3.3. Serine</title><p>Serine is the second frequently used AA fundamental for cancer cell survival. Serine has been shown to promote the growth of a variety of tumors through the lipid metabolism pathway (sphingolipids, phospholipids, and ceramide) [<xref rid="B72-nutrients-17-02813" ref-type="bibr">72</xref>,<xref rid="B73-nutrients-17-02813" ref-type="bibr">73</xref>], AAs homeostasis, epigenetic regulation, and redox balance [<xref rid="B74-nutrients-17-02813" ref-type="bibr">74</xref>,<xref rid="B75-nutrients-17-02813" ref-type="bibr">75</xref>,<xref rid="B76-nutrients-17-02813" ref-type="bibr">76</xref>]. Moreover, cancer cells exploit serine as a major source of one-carbon units to sustain the folate cycle, thereby rendering them dependent on either extracellular serine uptake or de novo serine synthesis to support maximal growth and proliferation [<xref rid="B75-nutrients-17-02813" ref-type="bibr">75</xref>,<xref rid="B77-nutrients-17-02813" ref-type="bibr">77</xref>]. Serine biosynthesis is activated by transcription factors or other mediators in rapidly growing tumors [<xref rid="B78-nutrients-17-02813" ref-type="bibr">78</xref>]. ATF3 and ATF4 are the major transcription factors that directly bind to the serine biosynthesis gene promoter to activate serine synthesis and growth of different tumors [<xref rid="B79-nutrients-17-02813" ref-type="bibr">79</xref>]. 3-Phospho-glycerate, an intermediate of glycolysis, is the main substrate for the synthesis of serine, which consists of a series of biochemical reactions catalyzed by four cytoplasmic and one mitochondrial enzyme [<xref rid="B12-nutrients-17-02813" ref-type="bibr">12</xref>]. Both synthesized and ingested serine are known to functionally support cancer development at all stages of tumorigenesis, from initiation to metastasis [<xref rid="B12-nutrients-17-02813" ref-type="bibr">12</xref>]. For these reasons, intervening on the serine biosynthesis pathway, including dietary restriction, seems a promising and relevant target to improve the effects of chemotherapy in cancer patients. In fact, serine restriction, both endogenous and exogenous, reduces tumor resistance to 5-FU or other chemotherapeutic treatments [<xref rid="B12-nutrients-17-02813" ref-type="bibr">12</xref>]. However, a recent in vivo study on murine colon cancer (CT26 cell line) with animals fed a special diet rich in all EAAs and containing serine, showed significant cancer cell death in vitro and a substantial slowdown of tumor progression in vivo [<xref rid="B16-nutrients-17-02813" ref-type="bibr">16</xref>].</p></sec><sec id="sec3dot4-nutrients-17-02813"><title>3.4. Arginine</title><p>Arginine is a NEAA considered semi-essential that plays a key role in cellular metabolism, synthesis of protein, nitric oxide, and polyamines, and immune system regulation. In addition, it is a direct activator of mTOR, a nutrient-sensing kinase strongly implicated in carcinogenesis. Some tumors exhibit a deficiency or absence of key enzymes for endogenous arginine synthesis (e.g., arginosuccinate synthase or ASS1). In over 70% of tumors, ASS1 transcription is suppressed, making them dependent on external arginine supplies for proliferation [<xref rid="B80-nutrients-17-02813" ref-type="bibr">80</xref>]. This has led to the development of therapies that deprive tumors of arginine, blocking their growth [<xref rid="B80-nutrients-17-02813" ref-type="bibr">80</xref>,<xref rid="B81-nutrients-17-02813" ref-type="bibr">81</xref>]. Furthermore, arginine is essential for T-lymphocyte function and the production of nitric oxide (NO), a mediator with variable effects in the tumor microenvironment [<xref rid="B82-nutrients-17-02813" ref-type="bibr">82</xref>]. However, some tumors express arginase, an enzyme that degrades arginine, contributing to local immunosuppression and thus promoting tumor progression [<xref rid="B82-nutrients-17-02813" ref-type="bibr">82</xref>]. The use of enzymes such as arginase or arginine deaminase to reduce arginine availability in the TME is the subject of clinical trials for the treatment of various types of cancer [<xref rid="B83-nutrients-17-02813" ref-type="bibr">83</xref>].</p></sec><sec id="sec3dot5-nutrients-17-02813"><title>3.5. Asparagine</title><p>Asparagine is an NEAA widely used by cells for the production of other nutrients such as glucose, proteins, lipids, and nucleotides. Asparagine can be produced by the cell from aspartate and glutamine by the enzyme asparagine synthase and plays a crucial role in the growth and spread of certain types of cancer [<xref rid="B84-nutrients-17-02813" ref-type="bibr">84</xref>]. Some tumors, particularly acute lymphoblastic leukemia (ALL) cells and solid tumors such as breast cancer, have low or absent expression of asparagine synthase and are therefore dependent on asparagine circulating in the blood for protein synthesis, proliferation, and metastasis [<xref rid="B85-nutrients-17-02813" ref-type="bibr">85</xref>,<xref rid="B86-nutrients-17-02813" ref-type="bibr">86</xref>]. The enzyme asparaginase is used to degrade asparagine in the bloodstream, reducing its availability and hindering tumor growth, especially in ALL [<xref rid="B87-nutrients-17-02813" ref-type="bibr">87</xref>]. However, in solid tumors, asparagine restriction alone does not provide therapeutic efficacy. In fact, tumor cells initiate reprogramming processes in response to asparagine deprivation [<xref rid="B88-nutrients-17-02813" ref-type="bibr">88</xref>].</p></sec><sec id="sec3dot6-nutrients-17-02813"><title>3.6. Proline and Glycine</title><p>The other two NEAAs needed by tumor cells are proline and glycine. They are very abundant in collagen; therefore, the dermis in primis represents an excellent endogenous reservoir. It has been demonstrated that proline availability influences collagen synthesis, promoting the maturation, plasticity, and heterogeneity of cancer cells [<xref rid="B89-nutrients-17-02813" ref-type="bibr">89</xref>]. Glycine is biosynthetically linked to serine, and both are important precursors for the synthesis of proteins, nucleic acids, and lipids, which are essential for the proliferation of tumor cells. In addition, their biosynthesis influences the antioxidant capacity of cells, promoting tumor homeostasis [<xref rid="B90-nutrients-17-02813" ref-type="bibr">90</xref>]. Moreover, studies on the proliferation rates of various tumor cell lines have revealed that glycine is consumed by cells in a highly proliferative state, while it is released by slowly proliferating cells [<xref rid="B91-nutrients-17-02813" ref-type="bibr">91</xref>].</p></sec><sec id="sec3dot7-nutrients-17-02813"><title>3.7. Essential Amino Acids (EAAs)</title><p>While tumor cells predominantly rely on NEAAs in large quantities [<xref rid="B10-nutrients-17-02813" ref-type="bibr">10</xref>], experimental evidence demonstrates that EAAs are also indispensable for sustaining tumor cell survival in culture [<xref rid="B52-nutrients-17-02813" ref-type="bibr">52</xref>,<xref rid="B53-nutrients-17-02813" ref-type="bibr">53</xref>,<xref rid="B54-nutrients-17-02813" ref-type="bibr">54</xref>,<xref rid="B73-nutrients-17-02813" ref-type="bibr">73</xref>]. It is well established that cancer cells increase the uptake of the branched-chained AAs (BCAAs), mostly leucine, to support their rapid proliferation through mTORC1 activation [<xref rid="B92-nutrients-17-02813" ref-type="bibr">92</xref>,<xref rid="B93-nutrients-17-02813" ref-type="bibr">93</xref>], while the other EAAs are necessary for protein synthesis and metabolism support of neoplastic cells.</p><p>To fulfill their metabolic requirements, cancer cells exploit macropinocytosis to internalize extracellular proteins, preferentially albumin, as a nutrient source, subsequently catabolizing them to release AAs, with a pronounced enrichment in NEAAs, for which they exhibit elevated uptake and utilization [<xref rid="B21-nutrients-17-02813" ref-type="bibr">21</xref>]. Beyond albumin, cancer cells utilize AAs derived from the breakdown of host tissues, notably skeletal muscle and skin, leading to sarcopenia, cachexia, and hypoalbuminemia, clinical indicators of disrupted systemic protein homeostasis and poor patient outcomes [<xref rid="B49-nutrients-17-02813" ref-type="bibr">49</xref>].</p><p>Considering what has been reported above, it is important to underline that limiting and/or modulating AAs availability in the TME and consequently inside the cancer cells could be an effective strategy to influence the tumor growth [<xref rid="B94-nutrients-17-02813" ref-type="bibr">94</xref>]. However, it is important to emphasize that reducing the availability of a single AA or group of AAs (as BCAAs) not only affects tumor cells, but also healthy cells that will have difficulty synthesizing proteins that ensure normal metabolism and the function of organic systems. Paradoxically, in the process of targeting the tumor, the host organism becomes progressively debilitated, resulting in widespread disruption of protein homeostasis. In hypercatabolic states such as cancer, preserving metabolic integrity and promoting an anabolic state, including muscle mass restoration, demands sufficient energy intake and a balanced supply of AAs, particularly all EAAs [<xref rid="B6-nutrients-17-02813" ref-type="bibr">6</xref>]. Since NEAAs are more represented than EAAs in dietary proteins, meeting the needs of EAAs is certainly much more difficult than meeting those of NEAAs [<xref rid="B52-nutrients-17-02813" ref-type="bibr">52</xref>]. Indeed, modulating the intake of some single AAs may be useful in experimental models [<xref rid="B95-nutrients-17-02813" ref-type="bibr">95</xref>], but it is far from practical application in humans. In conclusion, the intake of nitrogen from AAs in both health and tumor cells is extremely complicated and multivarious must always be considered in its complexity [<xref rid="B96-nutrients-17-02813" ref-type="bibr">96</xref>].</p></sec></sec><sec id="sec4-nutrients-17-02813"><title>4. Amino Acids in Experimental Models of Cancer</title><sec id="sec4dot1-nutrients-17-02813"><title>4.1. The Traditional Approach: A Single AA as a Drug</title><p>Despite the recognized importance of NEAAs in cancer cell metabolism, their therapeutic restriction has shown limited efficacy, as tumor cells can synthesize NEAAs de novo from metabolic intermediates and/or EAAs as needed [<xref rid="B97-nutrients-17-02813" ref-type="bibr">97</xref>]. Indeed, as already mentioned, cancer cells can increase BCAAs metabolism to stimulate tumor growth [<xref rid="B91-nutrients-17-02813" ref-type="bibr">91</xref>,<xref rid="B92-nutrients-17-02813" ref-type="bibr">92</xref>].</p><p>Some studies have found that leucine supplementation promotes cancer growth and aggressiveness [<xref rid="B36-nutrients-17-02813" ref-type="bibr">36</xref>] and, although it was observed as early as 1954, that tumors utilize plasma proteins (above all albumin) more efficiently than free [14C]-leucine [<xref rid="B20-nutrients-17-02813" ref-type="bibr">20</xref>]. Leucine deprivation inhibited cell proliferation and induced apoptosis of MDA-MB-231 and MCF-7 breast cancer cells in fatty acid synthase (FASN)-dependent manners [<xref rid="B98-nutrients-17-02813" ref-type="bibr">98</xref>]. These observations suggest that the availability of leucine may have pro-tumorigenic effects and antitumor effects [<xref rid="B36-nutrients-17-02813" ref-type="bibr">36</xref>]. However, other studies show that a diet rich in leucine (3%) led to a metabolic shift in the Walker-256 rat tumor towards a less glycolytic profile associated with a decrease in tumor aggressiveness and the number of metastatic sites [<xref rid="B99-nutrients-17-02813" ref-type="bibr">99</xref>]. To date, evidence remains insufficient to establish a definitive causal relationship between leucine and cancer cell proliferation [<xref rid="B34-nutrients-17-02813" ref-type="bibr">34</xref>].</p><p>Other studies showed that a lower-BCAAs diet impedes pancreatic ductal adenocarcinoma (PDAC) development in mouse models. Indeed, BCAA-aminotransferase-2 (BCAT2)-mediated BCAAs catabolism is critical for the development of PDAC [<xref rid="B100-nutrients-17-02813" ref-type="bibr">100</xref>]. Furthermore, high levels of dietary BCAAs intake promoted colon-rectal cancer (CRC) tumorigenesis in chemical-induced CRC and xenograft mouse models through inhibition of BCAAs metabolism and chronic activation of mTORC1 [<xref rid="B101-nutrients-17-02813" ref-type="bibr">101</xref>]. Both the mRNA and protein levels of BCAT2 were decreased in tumor tissues of patients with CRC compared to those in normal tissues. Furthermore, the accumulation of BCAAs caused by BCAT2 deficiency facilitated the chronic activation of mTORC1, thereby mediating the oncogenic effect of BCAA [<xref rid="B101-nutrients-17-02813" ref-type="bibr">101</xref>].</p><p>In addition, methionine-deficient diets but supplemented with cysteine, taurine, or both have demonstrated marked antitumor activity in animal models of colon cancer (CT26 cell line), as well as increased survival of mice with disseminated ovarian cancer (ID8 Tp53&#8722;/&#8722; cells) and renal cell carcinoma [<xref rid="B102-nutrients-17-02813" ref-type="bibr">102</xref>]. This is not surprising because methionine occupies the N terminus of all eukaryotic proteins, as it corresponds to the start codon of mRNA for protein synthesis. Therefore, its deficiency hinders the synthesis of new proteins (structural and enzymatic) that are essential for the tumor cell to multiply.</p><p>Unfortunately, the findings from previous studies on the role of AAs in inhibiting or promoting tumor progression have been inconsistent and often contradictory. There is no clear evidence that a single AA, or a small group of AAs, can independently influence tumor growth. This may be because such studies have tended to treat individual AAs (e.g., leucine) or small combinations as conventional drugs, assuming they exert specific, isolated pharmacological effects. In reality, AAs function as integral components of a highly interconnected metabolic network, engaging in numerous interdependent biochemical pathways. Modifying the concentration of one or a few AAs can markedly disrupt the balance between EAAs and NEAAs (EAA/NEAA ratio), thereby influencing cellular metabolism in complex and often unpredictable ways, sometimes producing effects opposite to those intended [<xref rid="B103-nutrients-17-02813" ref-type="bibr">103</xref>,<xref rid="B104-nutrients-17-02813" ref-type="bibr">104</xref>,<xref rid="B105-nutrients-17-02813" ref-type="bibr">105</xref>].</p><p>Before proceeding further, it is essential to address a critical concept: the role of AAs within the broader metabolic framework of living organisms.</p><p>Unlike conventional pharmacological agents, a single AA should not be viewed in isolation, but rather as a metabolically active molecule that interacts with and modulates numerous components within an intricate biochemical network. Pharmacology often focuses on single drug entities interacting with specific receptors to elicit a therapeutic effect. In fact, drugs exhibit high affinity and selectivity for specific molecular targets, often cell surface receptors, to trigger downstream signaling cascades and achieve a desired therapeutic outcome [<xref rid="B106-nutrients-17-02813" ref-type="bibr">106</xref>]. However, this reductionist approach may not be entirely applicable to endogenous molecules like AAs. These molecules are not xenobiotics but rather integral components of the overly complex and interconnected network of metabolism, participating in a multitude of biochemical reactions essential for life. AAs occupies central roles within the metabolic web, serving as substrates for protein synthesis, precursors for various biomolecules, energy sources through catabolic pathways, and key regulators of metabolic enzymes and signaling pathways [<xref rid="B107-nutrients-17-02813" ref-type="bibr">107</xref>,<xref rid="B108-nutrients-17-02813" ref-type="bibr">108</xref>].</p><p>We believe that to achieve specific and predictable metabolic effects using AAs, a strategy that leverages the synergistic interactions within the metabolic network is essential. Because metabolic pathways are interdependent and modulating one point in a pathway can have consequences elsewhere in the network, we postulate that combinations of AAs can be used to exert coordinated effects at multiple regulatory points within a specific pathway or across interconnected pathways to achieve a desired outcome. In addition, specific combinations of AAs can exhibit synergistic effects, where the combined effect is greater than the sum of the individual effects. This can lead to more potent and targeted modulation of metabolic pathways. Therefore, the research approaches should shift towards understanding and exploiting the synergistic actions of carefully designed and balanced EAAs mixtures, because they can provide a more physiological and sustainable approach to metabolic modulation. For these reasons, we believe that the conflicting results of previous studies depend on seeking and considering the effect of a single AA, when instead the proteinogenic AAs are twenty and their stoichiometric ratios are in dynamic equilibrium as a function of cellular metabolism. Crucially, the rate-limiting factor in this system is the simultaneous availability of all EAAs, which governs the efficiency and balance of anabolic processes [<xref rid="B50-nutrients-17-02813" ref-type="bibr">50</xref>]. For instance, the anabolic and metabolic effects of leucine are contingent upon the availability of all other EAAs in sufficient amounts to support and sustain cellular biosynthesis. Nevertheless, a substantial body of research has investigated the impact of individual AAs on cellular metabolism in isolation, disregarding these interdependencies [<xref rid="B109-nutrients-17-02813" ref-type="bibr">109</xref>]. Only a limited number of investigations have attempted to distinguish the metabolic impacts of EAAs from those of NEAAs [<xref rid="B110-nutrients-17-02813" ref-type="bibr">110</xref>]. This distinction is even less explored in the context of tumor cells, despite evidence showing that alterations in the EAA/NEAA ratio can significantly influence cellular metabolism [<xref rid="B103-nutrients-17-02813" ref-type="bibr">103</xref>,<xref rid="B104-nutrients-17-02813" ref-type="bibr">104</xref>]. Moreover, the restriction of specific EAAs and NEAAs, including leucine, with or without valine and isoleucine, as well as glycine, serine, glutamine, asparagine, and methionine, has been shown to affect tumor growth [<xref rid="B73-nutrients-17-02813" ref-type="bibr">73</xref>].</p></sec><sec id="sec4dot2-nutrients-17-02813"><title>4.2. The Innovative Approach: A Specifically Designed EAAs Mixture</title><p>It is well established that in all cells, protein synthesis and autophagy are dynamically interconnected and tightly regulated processes. They are influenced both by the availability of substrates, particularly AAs, required for biosynthesis, and by fluctuations in cellular energy status (ATP levels), which reciprocally affect one another. Among intracellular processes, protein synthesis is one of the most energy-intensive, consuming substantial amounts of ATP and converting it into AMP during the formation of hundreds of peptide bonds required to assemble a single protein. As ATP consumption increases, AMP levels rise proportionally. These shifts in ATP and AMP concentrations directly modulate the activity of key regulatory pathways&#8212;specifically mTORC1 and AMPK&#8212;that determine the timing, frequency, and extent of both protein synthesis and autophagy [<xref rid="B34-nutrients-17-02813" ref-type="bibr">34</xref>]. Based on this understanding, it can be inferred that altering the EAA/NEAA ratio in the TME to favor EAAs may stimulate robust protein synthesis, leading to elevated ATP consumption and a subsequent increase in ADP and AMP levels [<xref rid="B103-nutrients-17-02813" ref-type="bibr">103</xref>]. The induction of protein synthesis promoted by excess EAAs could be inhibited by the reduced availability of NEAAs needed to complete the synthesis. As a result, the cell must synthesize NEAAs endogenously, further increasing ATP consumption and thereby promoting autophagy. However, autophagy can also be triggered by mTORC2 independent of mTORC1 [<xref rid="B111-nutrients-17-02813" ref-type="bibr">111</xref>]. These authors demonstrated that fasting reduces the availability of NEAAs, particularly glutamine, triggering autophagy independently of TORC1 inactivation. When glutamine demand is not met, especially due to insufficient intake of EAAs precursors, the cell resorts to muscle protein catabolism, contributing to cancer-related sarcopenia and cachexia [<xref rid="B111-nutrients-17-02813" ref-type="bibr">111</xref>].</p><p>Notably, it was observed that the addition of a mixture containing all EAAs in stoichiometric ratio to the culture medium of in vitro isolated three human tumor cell lines [melanoma (M14), breast cancer cell (MCF7) and colon cancer cells (HCT116)] caused the death of the tumor cells [<xref rid="B112-nutrients-17-02813" ref-type="bibr">112</xref>] and, at the same time, enhanced the effect of the chemotherapeutic drug Doxorubicin [<xref rid="B113-nutrients-17-02813" ref-type="bibr">113</xref>]. Subsequently, in five human tumor cell lines, it has been demonstrated that altering the EAA/NEAA ratio with excess of EAAs (84%), it is possible to inhibit proteasomes and promote autophagy and triggering apoptosis without damage to normal cells [<xref rid="B33-nutrients-17-02813" ref-type="bibr">33</xref>]. Recently, in vivo experiments showed that an EAAs-rich diet reduced tumor growth, induced endoplasmic reticulum (ER) stress, and inhibited mTOR activity [<xref rid="B34-nutrients-17-02813" ref-type="bibr">34</xref>]. In tumor cells in vitro, the EAAs mixture increased BCAAs oxidation, decreased glycolysis, ATP levels, redox potential, and intracellular NEAAs content. EAAs-induced NEAAs deficiency led to increased ER stress, mTOR inactivation, and apoptosis, without affecting the survival and proliferation of non-tumor cells [<xref rid="B34-nutrients-17-02813" ref-type="bibr">34</xref>]. Moreover, it has been demonstrated that in vivo the administration of a specific mixture of all EAAs in a stoichiometric ratio increases intracellular EAAs levels while reducing concentrations of glutamate, glycine, aspartate, and alanine. This biochemical profile mimics a starvation-like response, primarily due to glutamate depletion, which subsequently activates mitochondrial catabolism of BCAAs and inhibits glycolysis (the Warburg effect) in favor of TCA cycle activation. These metabolic shifts induced by excess of EAAs lead to tumor growth suppression, increased ER stress, reduced mTORC1 activity, enhanced apoptosis, and tumor cell death. In contrast, the metabolic and biosynthetic functions of non-tumor cells are effectively supported by the availability of EAAs [<xref rid="B34-nutrients-17-02813" ref-type="bibr">34</xref>] (<xref rid="nutrients-17-02813-f002" ref-type="fig">Figure 2</xref>). It is therefore evident that in tumor cells the &#8220;classical&#8221; concept of EAAs and NEAAs does not follow the traditional definition, as EAAs and NEAAs play highly flexible roles in protein synthesis and energy in tumor cells [<xref rid="B16-nutrients-17-02813" ref-type="bibr">16</xref>].</p><p>More recent in vitro and in vivo evidence, including studies on murine (CT26) and human (HCT116) colon cancer cells, indicates that an excess of EAAs in the culture medium or diet exerts significant cytostatic effects on cancer cells when provided at levels sufficient to markedly increase the EAA/NEAA ratio, typically &lt;&lt;0.9 in dietary proteins, to value well &gt;&gt;1. Furthermore, an additional noteworthy finding is that animals bearing tumors and fed an EAAs-enriched diet exhibit preservation of muscle mass [<xref rid="B35-nutrients-17-02813" ref-type="bibr">35</xref>]. The EAAs-rich mixture used in these studies is summarized in <xref rid="nutrients-17-02813-t001" ref-type="table">Table 1</xref>. It is important to emphasize that the EAAs mixture described in <xref rid="nutrients-17-02813-t001" ref-type="table">Table 1</xref> has proven effective in preventing and treating hypercatabolic conditions in both experimental models and clinical settings [<xref rid="B6-nutrients-17-02813" ref-type="bibr">6</xref>,<xref rid="B7-nutrients-17-02813" ref-type="bibr">7</xref>,<xref rid="B8-nutrients-17-02813" ref-type="bibr">8</xref>]. This efficacy is attributed to its ability to enhance cellular metabolism by stimulating mitochondrial biogenesis and activity, activating mTORC1, and inducing eNOS expression as previously described [<xref rid="B114-nutrients-17-02813" ref-type="bibr">114</xref>].</p><p>If the EAA/NEAA ratio in the tumor cell is shifted in favor of EAAs, it favors the consumption of substantial amounts of ATP to build the thousands of peptide bonds needed for protein synthesis, consequently leading to an increase in ADP and AMP. This activates AMPK, which, in turn, inhibits mTORC1 and activates autophagy, providing substrates to support the new production of ATP and a decrease in the availability of NEAAs (<xref rid="nutrients-17-02813-f003" ref-type="fig">Figure 3</xref>). These changes create a vicious cycle that inhibits cell proliferation and induces apoptosis [<xref rid="B107-nutrients-17-02813" ref-type="bibr">107</xref>].
<table-wrap position="anchor" id="nutrients-17-02813-t001" orientation="portrait"><object-id pub-id-type="pii">nutrients-17-02813-t001_Table 1</object-id><label>Table 1</label><caption><p>Composition of EAAs-mix for in vitro and in vivo experiments. BCAA = branched-chain AAs. The EAAs mix provided nitrogen as free AAs, where the EAAs are in excess (84%) compared to NEAAs (16%) (EAA/NEAA = 6.14). L-cystine (NEAA) was added to satisfy the requirements for sulfur AAs while keeping methionine content to a minimum. Additionally, L-serine (NEAA) was included to optimally sustain the folate and methionine cycle, as well as energy production. Ornithine alpha-ketoglutarate is a key intermediate in the Krebs cycle and serves as a precursor for polyamines, proline, and glutamine. <italic toggle="yes">N</italic>-acetylcysteine is a derivative of cysteine that acts mainly as a precursor to glutathione, a major intracellular antioxidant.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Free AAs Composition of EAAs-Mix</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">L-Leucine (BCAA)</td><td align="center" valign="middle" rowspan="1" colspan="1">13.53</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L-Isoleucine (BCAA)</td><td align="center" valign="middle" rowspan="1" colspan="1">9.65</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L-Valine (BCAA)</td><td align="center" valign="middle" rowspan="1" colspan="1">9.65</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L-Lysine</td><td align="center" valign="middle" rowspan="1" colspan="1">11.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L-Threonine</td><td align="center" valign="middle" rowspan="1" colspan="1">8.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L-Histidine</td><td align="center" valign="middle" rowspan="1" colspan="1">11.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L-Phenylalanine</td><td align="center" valign="middle" rowspan="1" colspan="1">7.73</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L-Methionine</td><td align="center" valign="middle" rowspan="1" colspan="1">4.35</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L-Tyrosine</td><td align="center" valign="middle" rowspan="1" colspan="1">5.80</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L-Tryptophan</td><td align="center" valign="middle" rowspan="1" colspan="1">3.38</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L-Cystine/Cysteine</td><td align="center" valign="middle" rowspan="1" colspan="1">8.20</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L-Serine</td><td align="center" valign="middle" rowspan="1" colspan="1">2.42</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ornithine-&#945;KG</td><td align="center" valign="middle" rowspan="1" colspan="1">2.42</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">N</italic>-acetylcysteine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.97</td></tr></tbody></table></table-wrap>
</p><p>Globally, these studies indicate that an excess of EAAs, leading to an increased EAA/NEAA ratio, exhibits remarkable antiproliferative properties, negatively influencing cancer cell survival, and supporting the health of normal cells (<xref rid="nutrients-17-02813-f002" ref-type="fig">Figure 2</xref>).</p></sec></sec><sec sec-type="subjects" id="sec5-nutrients-17-02813"><title>5. Amino Acids in Cancer Patients</title><p>In cancer therapy, AA metabolism can be approached from different angles: inhibition of either AA transporters, AA biosynthesis, or restriction/depletion of a single AA. For example, pharmacological inhibition of glutaminase has yielded encouraging results by inhibiting tumor cell proliferation in several cancer types, including triple-negative breast cancer, acute myeloid leukemia, and non-small cell lung cancer [<xref rid="B94-nutrients-17-02813" ref-type="bibr">94</xref>]. Other evidence suggests that the administration of the enzyme asparaginase in the treatment of pediatric acute lymphoblastic leukemia improved the cure rate [<xref rid="B115-nutrients-17-02813" ref-type="bibr">115</xref>]. Indeed, while most cells express asparagine synthase, the enzyme that converts aspartate to asparagine, in immature and leukemic lymphocytes, its expression is insufficient, making these cells auxotrophic for asparagine. Consequently, treatment with asparaginase kills leukemic cells, although it is associated with several manageable acute toxicities [<xref rid="B116-nutrients-17-02813" ref-type="bibr">116</xref>].</p><p>In the clinical setting, when tumor cells selectively depend on the exogenous supply of specific AAs, their depletion in the blood flow will lead to intracellular deficiency of the same, cessation of synthesis, hence of proliferation, and, finally, induction of apoptosis [<xref rid="B117-nutrients-17-02813" ref-type="bibr">117</xref>]. Recently, a clinical study enrolled six healthy, middle-aged participants who were placed on a low-methionine diet (~2.92 mg/kg/day) for three weeks, representing an approximately 83% reduction in daily methionine intake. In this regimen, 75% of total protein was supplied by a methionine-free medical formula (Hominex-2, Abbott Nutrition, Columbus, OH, USA), while the remaining 25% was derived from low-methionine foods such as fruits, vegetables, and refined grains. Methionine restriction has been shown to cause metabolic changes like those observed in colorectal tumor-bearing mice, including inhibition of nucleotide synthesis metabolism [<xref rid="B118-nutrients-17-02813" ref-type="bibr">118</xref>]. It is therefore hypothesized that methionine restriction in cancer patients could inhibit tumor progression similarly to what is well documented in experimental mouse models [<xref rid="B119-nutrients-17-02813" ref-type="bibr">119</xref>]. Currently, AAs under investigation in clinical trials (phase I or II) for therapeutic deprivation include asparagine, glutamine, arginine, and methionine [<xref rid="B94-nutrients-17-02813" ref-type="bibr">94</xref>].</p><p>AAs restriction strategies may hold theoretical promise for human cancer therapy, partly due to their lower toxicity compared to conventional chemotherapeutics. However, prior to clinical translation, a more comprehensive understanding of the metabolic dependencies and TME specific to each cancer type is essential. Furthermore, the therapeutic efficacy of interventions that modulate AA availability is influenced not only by tumor type but also by the anatomical context and functional status of the immune system [<xref rid="B119-nutrients-17-02813" ref-type="bibr">119</xref>]. It is also important to recognize, as previously noted, that AA restriction impacts not only malignant cells but also normal tissues. Consequently, a detailed characterization of its effects on healthy cells is essential. Overall, therapeutic approaches based on the selective restriction of specific AAs remain insufficiently characterized and warrant further investigation [<xref rid="B120-nutrients-17-02813" ref-type="bibr">120</xref>].</p><p>Another approach involves integration with BCAAs. In a multicenter, randomized, controlled trial, long-term oral supplementation with BCAAs (12 g/day) in cirrhotic patients has been shown to be effective in limiting the development of liver cancer [<xref rid="B121-nutrients-17-02813" ref-type="bibr">121</xref>,<xref rid="B122-nutrients-17-02813" ref-type="bibr">122</xref>]. Higher levels of dietary BCAAs intake are not associated with an increase in CRC risk, but they may be related to a reduced risk of sigmoid colon cancer [<xref rid="B123-nutrients-17-02813" ref-type="bibr">123</xref>]. Conversely, high blood levels of BCAAs are an early event in the development of pancreatic cancer [<xref rid="B124-nutrients-17-02813" ref-type="bibr">124</xref>]. Furthermore, evidence indicates that elevated levels of BCAAs in plasma are positively associated with pancreatic cancer risk [<xref rid="B125-nutrients-17-02813" ref-type="bibr">125</xref>]. However, epidemiological studies have shown that the incidence of liver cancer in cirrhotic patients is reduced by chronic intake of BCAAs [<xref rid="B126-nutrients-17-02813" ref-type="bibr">126</xref>,<xref rid="B127-nutrients-17-02813" ref-type="bibr">127</xref>,<xref rid="B128-nutrients-17-02813" ref-type="bibr">128</xref>]. The existing literature is fragmented and frequently contradictory, largely due to heterogeneity in experimental designs and the specific AAs examined. In our view, a major limitation lies in the predominant focus on branched-chain AAs (BCAAs) in isolation, rather than on the use of a complete mixture of all EAAs in appropriate stoichiometric ratios.</p><sec><title>Amino Acids as Prevention or Treatment of Cancer Cachexia</title><p>Cancer patients, especially those experiencing cachexia, inflammation, or undergoing intensive treatments (chemo- or radiotherapy) require higher protein intake than healthy individuals. Guidelines recommend a total protein intake ranging between 1.0 and 2.0 g/kg/day, with 1.2&#8211;1.5 g/kg/day often cited for intermediate needs and up to 2.0 g/kg/day in more severe cases. Correspondingly, EAAs targets are suggested to be &#8805;1.2 g/kg/day in hypercatabolic or cachectic patients [<xref rid="B129-nutrients-17-02813" ref-type="bibr">129</xref>].</p><p>Most research on AAs in cancer patients has focused on strategies to prevent or attenuate the loss of muscle mass (MM). Cancer-associated malnutrition is highly prevalent and negatively affects both clinical outcomes and quality of life. In this population, the most pronounced manifestation of malnutrition is a marked reduction in MM, ranging from sarcopenia to cachexia, which may occur independently of body weight or fat mass [<xref rid="B130-nutrients-17-02813" ref-type="bibr">130</xref>]. The reported prevalence of malnutrition varies widely, from 20% to 70%, depending on tumor type, disease stage, and clinical context [<xref rid="B131-nutrients-17-02813" ref-type="bibr">131</xref>,<xref rid="B132-nutrients-17-02813" ref-type="bibr">132</xref>]. Systemic inflammation and other metabolic disturbances are present in 34% of patients with colorectal cancer (CRC) undergoing curative treatment, in 75% of cancer patients at hospital admission [<xref rid="B133-nutrients-17-02813" ref-type="bibr">133</xref>], and in 55&#8211;85% of patients with advanced disease [<xref rid="B134-nutrients-17-02813" ref-type="bibr">134</xref>].</p><p>Cancer cachexia is characterized by a negative energy balance and profound disturbances in protein metabolism. One major contributor to muscle loss is the increased splanchnic sequestration of AAs, particularly EAAs, to support hepatic activity in response to the intense inflammatory state [<xref rid="B135-nutrients-17-02813" ref-type="bibr">135</xref>]. As the primary reservoirs of AAs, skeletal muscles are significantly depleted to meet the elevated systemic demand for EAAs, including branched-chain amino acids (BCAAs). Additionally, the heightened energy requirements may stimulate muscle protein breakdown to supply AAs substrates for gluconeogenesis and glycogen synthesis, further exacerbating the loss of skeletal muscle mass [<xref rid="B136-nutrients-17-02813" ref-type="bibr">136</xref>]. Consequently, the protein requirements of cancer patients are typically higher (1.2&#8211;2.0 g/kg/day) than those of healthy individuals (0.8 g/kg/day), especially in the presence of additional catabolic factors such as physical inactivity or age-related comorbidities [<xref rid="B131-nutrients-17-02813" ref-type="bibr">131</xref>,<xref rid="B132-nutrients-17-02813" ref-type="bibr">132</xref>].</p><p>Treatment strategies and clinical outcomes for malnutrition in cancer patients differ according to the presence or absence of underlying metabolic derangements. &#8220;Starvation-type&#8221; malnutrition results primarily from a straightforward deficit in nutrient and energy intake, whereas &#8220;inflammatory-type&#8221; malnutrition, commonly termed cancer cachexia, is driven by complex metabolic alterations associated with systemic inflammation [<xref rid="B132-nutrients-17-02813" ref-type="bibr">132</xref>]. The anabolic resistance observed in these patients can be mitigated through the administration of AA mixtures enriched with leucine. Among the essential amino acids, BCAAs have been the most extensively studied in oncologic nutrition due to their potent ability to stimulate muscle protein synthesis. Unfortunately, the studies have many critical issues due to different causes that make the results heterogeneous and contrasting [<xref rid="B137-nutrients-17-02813" ref-type="bibr">137</xref>]. However, as described in a previous section (<xref rid="sec3dot2-nutrients-17-02813" ref-type="sec">Section 3.2</xref>), a review of the literature suggests that leucine enhances protein synthesis through activation of mTORC1, while simultaneously reducing protein degradation. This dual action contributes to the preservation of MM, augments the beneficial effects of physical activity on sarcopenia, and may also attenuate cancer progression and prevent cancer-associated cachexia (see <xref rid="nutrients-17-02813-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B138-nutrients-17-02813" ref-type="bibr">138</xref>,<xref rid="B139-nutrients-17-02813" ref-type="bibr">139</xref>]. In patients with hypercatabolic syndrome, as well as in experimental models, administration of a mixture of all EAAs, formulated in a human-tailored stoichiometric ratio, has been shown to counteract sarcopenia and protein dysregulation. This intervention promotes anabolism by enhancing mitochondrial activity, inducing mitochondrial biogenesis, and activating both mTORC1 and endothelial nitric oxide synthase (eNOS) [<xref rid="B6-nutrients-17-02813" ref-type="bibr">6</xref>,<xref rid="B140-nutrients-17-02813" ref-type="bibr">140</xref>,<xref rid="B141-nutrients-17-02813" ref-type="bibr">141</xref>,<xref rid="B142-nutrients-17-02813" ref-type="bibr">142</xref>]. Collectively, these effects not only support muscle protein synthesis but also improve overall cellular energy metabolism, highlighting the clinical importance of targeted nutritional support in enhancing physical performance, particularly in hypercatabolic or malnourished patients [<xref rid="B143-nutrients-17-02813" ref-type="bibr">143</xref>].</p></sec></sec><sec id="sec6-nutrients-17-02813"><title>6. Does Food Integration with EAAs Promote Cancer?</title><p>It is commonly agreed that nutritional choices can influence the risk of developing certain cancers [<xref rid="B144-nutrients-17-02813" ref-type="bibr">144</xref>]. Major organizations, including the National Cancer Institute, Cancer Research UK, and the European Society for Clinical Nutrition and Metabolism (ESPEN), have issued nutritional guidelines for cancer patients that recommend a &#8220;healthy&#8221; diet, with adequate energy and nutritional intake, particularly regarding the protein amount [<xref rid="B131-nutrients-17-02813" ref-type="bibr">131</xref>]. Unfortunately, nothing is said about the quality of the proteins. Many nutritional approaches have investigated fasting and caloric restriction, fat and carbohydrate balance, the ketogenic diet, protein restriction, and modulation of EAAs or NEAAs. Since cancer cells are highly dependent on NEAAs, research has focused primarily on their dietary manipulation [<xref rid="B120-nutrients-17-02813" ref-type="bibr">120</xref>]. However, it should be emphasized that dietary manipulation affects not only the tumor but also all physiological systems. Under normal conditions, approximately 70% of the EAAs released through muscle protein breakdown are reincorporated into newly synthesized muscle proteins. In patients with neoplastic disease, this recycling efficiency is markedly reduced; instead, amino acids are released into circulation and subsequently deaminated to provide energy and sustain other metabolic processes [<xref rid="B6-nutrients-17-02813" ref-type="bibr">6</xref>,<xref rid="B105-nutrients-17-02813" ref-type="bibr">105</xref>]. As a result, supplementation with BCAAs alone, despite their elevated requirement, is insufficient to sustain muscle protein synthesis. This is primarily because the limited availability of other EAAs rapidly becomes the rate-limiting factor [<xref rid="B105-nutrients-17-02813" ref-type="bibr">105</xref>]. Therefore, an anabolic state cannot occur without the availability of all EAAs in adequate quantities.</p><p>The positive effect of EAAs supplementation has been observed in numerous experimental conditions, including chemotherapy [<xref rid="B113-nutrients-17-02813" ref-type="bibr">113</xref>], and is based on the stimulation of anabolism by activating the enzyme eNOS with consequent mitochondrial genesis and reduction in reactive oxygen species (ROS) [<xref rid="B142-nutrients-17-02813" ref-type="bibr">142</xref>], as well as the activation of mTORC1, with increased protein synthesis [<xref rid="B145-nutrients-17-02813" ref-type="bibr">145</xref>]. To meet its demand, tumors extract nutrients from the surrounding TME and also manipulate the behavior of stromal cells. In addition, autophagy, both in tumor and stromal cells, helps to maintain nutrient availability during tumor development [<xref rid="B120-nutrients-17-02813" ref-type="bibr">120</xref>]. Within the cell, a balanced protein synthesis and degradation is crucial for preserving cell homeostasis. Hence, increased proteolysis and reduced protein synthesis (protein&#8217;s disarrangement) have been associated with the severe depletion of body protein reserves, eventually resulting in malnutrition. This may impact the progression of disease-associated conditions, including tumors [<xref rid="B128-nutrients-17-02813" ref-type="bibr">128</xref>].</p><p>In recent years, the potential of leucine to improve muscle wasting in cancer cachexia has been extensively studied [<xref rid="B36-nutrients-17-02813" ref-type="bibr">36</xref>]. However, it should be noted that in these studies, patients supplemented with leucine obviously received a protein-rich diet from which they obtained the other necessary EAAs. Although leucine is described as the most effective of the three BCAAs in stimulating muscle protein synthesis, isoleucine and valine also play a significant role. In fact, their deficiency inhibits muscle growth despite the presence of leucine. Furthermore, exclusive supplementation with high doses of BCAAs can generate competitive transport mechanisms with other AAs, reducing their availability and consequently limiting biosynthesis [<xref rid="B105-nutrients-17-02813" ref-type="bibr">105</xref>]. Therefore, to counteract the hypercatabolic state, impaired protein synthesis, and reduced intracellular AAs transport observed in metabolic disorders, it is essential to provide a supplement containing all EAAs in appropriate proportions. Indeed, AAs depletion in the TME not only restricts local availability but also drives a systemic reduction, contributing to muscle wasting, impaired protein metabolism, and broader metabolic dysfunction, with significant negative consequences for patient outcomes.</p><p>Previously, in a randomized phase II study involving 25 cachectic subjects with advanced cancer, the administration of 8 g/day of EAAs for 8 weeks was associated with the maintenance of residual MM, a significant increase in strength and total serum albumin, with a decrease in blood levels of ROS [<xref rid="B146-nutrients-17-02813" ref-type="bibr">146</xref>]. Given that, unlike healthy cells, tumor cells do not exhibit a clear distinction between EAAs and NEAAs and are reliant on NEAAs, the administration of all EAAs in a stoichiometric ratio may represent a promising strategy. This approach could alter the EAA/NEAA ratio balance, thereby modulating the TME, inhibiting tumor progression, preserving MM, and improving systemic outcomes, as demonstrated in vivo experimental models [<xref rid="B34-nutrients-17-02813" ref-type="bibr">34</xref>,<xref rid="B35-nutrients-17-02813" ref-type="bibr">35</xref>].</p><p>Although the available findings on EAAs supplementation in cancer patients are encouraging, it should be noted that most clinical evidence derives from phase II studies involving relatively small patient cohorts. Large-scale randomized clinical trials are still lacking, warranting caution in interpreting and applying these results in clinical practice. Moreover, responses to EAAs supplementation may vary among different tumor types, influenced by factors such as dosage, composition of the mixture, and duration of administration.</p></sec><sec sec-type="conclusions" id="sec7-nutrients-17-02813"><title>7. Conclusions</title><p>Both quality and quantity of EAAs (EAA/NEAA ratio) introduced by nutrition would regulate an efficient balance between protein synthesis and protein turnover [<xref rid="B105-nutrients-17-02813" ref-type="bibr">105</xref>,<xref rid="B147-nutrients-17-02813" ref-type="bibr">147</xref>]. Based on current evidence, we propose that continuous supplementation of cancer patients with a complete mixture of EAAs, formulated in a stoichiometric ratio aligned with human cellular requirements, may enhance protein synthesis while shifting the typical dietary EAA/NEAA ratio toward values &#8805;1. This metabolic shift could impose stress on tumor cells, eliciting an epigenetic response marked by increased protein synthesis and heightened ATP consumption. However, in the context of excessive EAAs and limited availability of NEAAs, efficient protein assembly in cancer cells would be impaired. To compensate, tumor cells may activate hyper-autophagy and de novo NEAAs synthesis, further elevating ATP demand and leading to increased ROS production and oxidative stress. These metabolic disturbances may suppress mTORC1 signaling, arrest protein synthesis, induce apoptosis, and ultimately promote cancer cell death.</p><p>In summary, current evidence supports the concept that supplementation with a complete mixture of EAAs may serve as a valuable adjunct to standard cancer therapies. This strategy has the potential to correct cancer-associated protein imbalances, improve patients&#8217; quality of life, and create a metabolic environment unfavorable to tumor progression. Nevertheless, well-designed clinical trials are needed to fully clarify the therapeutic efficacy and safety of EAAs supplementation in oncology.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank Cristina Antonelli for the linguistic revision of the text.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, G.C. and E.P.; methodology, G.C.; software, G.C. and C.R.; validation, E.P. and F.S.D.; investigation, G.C. and E.P.; writing&#8212;original draft preparation, G.C. and E.P.; writing&#8212;review and editing, F.S.D., C.R. and G.C.; supervision, G.C.; project administration, G.C.; funding acquisition, G.C. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>F.S.D. was employed by Nutri-Research s.r.l. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Arg-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Arginase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ASS1</td><td align="left" valign="middle" rowspan="1" colspan="1">Arginosuccinate synthase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BCAA</td><td align="left" valign="middle" rowspan="1" colspan="1">Branched-chain amino acids</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CRC</td><td align="left" valign="middle" rowspan="1" colspan="1">Colorectal cancer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EAAs</td><td align="left" valign="middle" rowspan="1" colspan="1">Essential amino acids</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">eNOS</td><td align="left" valign="middle" rowspan="1" colspan="1">Endothelial nitric oxide synthase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IDO1</td><td align="left" valign="middle" rowspan="1" colspan="1">Indoleamine 2,3 dioxygenase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MM</td><td align="left" valign="middle" rowspan="1" colspan="1">Muscle mass</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NEAA</td><td align="left" valign="middle" rowspan="1" colspan="1">Non-essential amino acids</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ROS</td><td align="left" valign="middle" rowspan="1" colspan="1">Reactive oxygen species</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TME</td><td align="left" valign="middle" rowspan="1" colspan="1">Tumor microenvironment</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-nutrients-17-02813"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anand</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kunnumakkara</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Sundaram</surname><given-names>C.</given-names></name><name name-style="western"><surname>Harikumar</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Tharakan</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>O.S.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>B.</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>B.B.</given-names></name></person-group><article-title>Cancer is a preventable disease that requires major lifestyle changes</article-title><source>Pharm. Res.</source><year>2008</year><volume>25</volume><fpage>2097</fpage><lpage>2116</lpage><comment>Erratum in: <italic toggle="yes">Pharm. Res. </italic><bold>2008</bold>, <italic toggle="yes">25</italic>, 2200</comment><pub-id pub-id-type="doi">10.1007/s11095-008-9661-9</pub-id><pub-id pub-id-type="pmid">18626751</pub-id><pub-id pub-id-type="pmcid">PMC2515569</pub-id></element-citation></ref><ref id="B2-nutrients-17-02813"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Heber</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tchekmedyian</surname><given-names>N.S.</given-names></name></person-group><article-title>Cancer anorexia and cachexia</article-title><source>Nutritional Oncology</source><person-group person-group-type="editor"><name name-style="western"><surname>Heber</surname><given-names>D.</given-names></name><name name-style="western"><surname>Blackburn</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Go</surname><given-names>V.L.</given-names></name></person-group><publisher-name>Academic Press</publisher-name><publisher-loc>San Diego, CA, USA</publisher-loc><year>1999</year><fpage>645</fpage><lpage>660</lpage></element-citation></ref><ref id="B3-nutrients-17-02813"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hall</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Marco</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Gallouzi</surname><given-names>I.E.</given-names></name></person-group><article-title>Inducible nitric oxide synthase (iNOS) in muscle wasting syndrome, sarcopenia, and cachexia</article-title><source>Aging</source><year>2011</year><volume>3</volume><fpage>702</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.18632/aging.100358</pub-id><pub-id pub-id-type="pmid">21832306</pub-id><pub-id pub-id-type="pmcid">PMC3184974</pub-id></element-citation></ref><ref id="B4-nutrients-17-02813"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Visvanathan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>I.M.</given-names></name></person-group><article-title>Undernutrition and anorexia in the older person</article-title><source>Gastroenterol. Clin. N. Am.</source><year>2009</year><volume>38</volume><fpage>393</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1016/j.gtc.2009.06.009</pub-id><pub-id pub-id-type="pmid">19699404</pub-id></element-citation></ref><ref id="B5-nutrients-17-02813"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ispoglou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Witard</surname><given-names>O.C.</given-names></name><name name-style="western"><surname>Duckworth</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Lees</surname><given-names>M.J.</given-names></name></person-group><article-title>The efficacy of essential amino acid supplementation for augmenting dietary protein intake in older adults: Implications for skeletal muscle mass, strength and function</article-title><source>Proc. Nutr. Soc.</source><year>2021</year><volume>80</volume><fpage>230</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1017/S0029665120008010</pub-id><pub-id pub-id-type="pmid">33315000</pub-id></element-citation></ref><ref id="B6-nutrients-17-02813"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Corsetti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Aquilani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Romano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Picca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Calvani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dioguardi</surname><given-names>F.S.</given-names></name></person-group><article-title>Protein-amino acid metabolism disarrangements: The hidden enemy of chronic age-related conditions</article-title><source>Nutrients</source><year>2018</year><volume>10</volume><elocation-id>391</elocation-id><pub-id pub-id-type="doi">10.3390/nu10040391</pub-id><pub-id pub-id-type="pmid">29565819</pub-id><pub-id pub-id-type="pmcid">PMC5946176</pub-id></element-citation></ref><ref id="B7-nutrients-17-02813"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aquilani</surname><given-names>R.</given-names></name><name name-style="western"><surname>D&#8217;Antona</surname><given-names>G.</given-names></name><name name-style="western"><surname>Baiardi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gambino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iadarola</surname><given-names>P.</given-names></name><name name-style="western"><surname>Viglio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pasini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Verri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barbieri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boschi</surname><given-names>F.</given-names></name></person-group><article-title>Essential amino acids and exercise tolerance in elderly muscle-depleted subjects with chronic diseases: A rehabilitation without rehabilitation?</article-title><source>Biomed. Res. Int.</source><year>2014</year><volume>2014</volume><elocation-id>341603</elocation-id><pub-id pub-id-type="doi">10.1155/2014/341603</pub-id><pub-id pub-id-type="pmid">25009815</pub-id><pub-id pub-id-type="pmcid">PMC4070286</pub-id></element-citation></ref><ref id="B8-nutrients-17-02813"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rondanelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Opizzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Antoniello</surname><given-names>N.</given-names></name><name name-style="western"><surname>Boschi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Iadarola</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pasini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aquilani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dioguardi</surname><given-names>F.S.</given-names></name></person-group><article-title>Effect of essential amino acid supplementation on quality of life, amino acid profile and strength in institutionalized elderly patients</article-title><source>Clin. Nutr.</source><year>2011</year><volume>30</volume><fpage>571</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2011.04.005</pub-id><pub-id pub-id-type="pmid">21636183</pub-id></element-citation></ref><ref id="B9-nutrients-17-02813"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Brien</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>I.B.</given-names></name><name name-style="western"><surname>Beckman</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>D.A.</given-names></name></person-group><article-title>Standards for reporting qualitative research: A synthesis of recommendations</article-title><source>Acad. Med.</source><year>2014</year><volume>89</volume><fpage>1245</fpage><lpage>1251</lpage><pub-id pub-id-type="doi">10.1097/ACM.0000000000000388</pub-id><pub-id pub-id-type="pmid">24979285</pub-id></element-citation></ref><ref id="B10-nutrients-17-02813"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Coloff</surname><given-names>J.L.</given-names></name></person-group><article-title>The diverse functions of non-essential amino acids in cancer</article-title><source>Cancers</source><year>2019</year><volume>11</volume><elocation-id>675</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11050675</pub-id><pub-id pub-id-type="pmid">31096630</pub-id><pub-id pub-id-type="pmcid">PMC6562791</pub-id></element-citation></ref><ref id="B11-nutrients-17-02813"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faubert</surname><given-names>B.</given-names></name><name name-style="western"><surname>Solmonson</surname><given-names>A.</given-names></name><name name-style="western"><surname>DeBerardinis</surname><given-names>R.J.</given-names></name></person-group><article-title>Metabolic reprogramming and cancer progression</article-title><source>Science</source><year>2020</year><volume>368</volume><fpage>eaaw5473</fpage><pub-id pub-id-type="doi">10.1126/science.aaw5473</pub-id><pub-id pub-id-type="pmid">32273439</pub-id><pub-id pub-id-type="pmcid">PMC7227780</pub-id></element-citation></ref><ref id="B12-nutrients-17-02813"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shunxi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xiaoxue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guanbin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Junyu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wanqian</surname><given-names>L.</given-names></name></person-group><article-title>Serine metabolic reprogramming in tumorigenesis, tumor immunity, and clinical treatment</article-title><source>Adv. Nutr.</source><year>2023</year><volume>14</volume><fpage>1050</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1016/j.advnut.2023.05.007</pub-id><pub-id pub-id-type="pmid">37187454</pub-id><pub-id pub-id-type="pmcid">PMC10509429</pub-id></element-citation></ref><ref id="B13-nutrients-17-02813"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shay</surname><given-names>C.</given-names></name><name name-style="western"><surname>Saba</surname><given-names>N.F.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>Y.</given-names></name></person-group><article-title>Cancer metabolism and carcinogenesis</article-title><source>Exp. Hematol. Oncol.</source><year>2024</year><volume>13</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1186/s40164-024-00482-x</pub-id><pub-id pub-id-type="pmid">38287402</pub-id><pub-id pub-id-type="pmcid">PMC10826200</pub-id></element-citation></ref><ref id="B14-nutrients-17-02813"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vander Heiden</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Cantley</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>C.B.</given-names></name></person-group><article-title>Understanding the Warburg effect: The metabolic requirements of cell proliferation</article-title><source>Science</source><year>2009</year><volume>324</volume><fpage>1029</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1126/science.1160809</pub-id><pub-id pub-id-type="pmid">19460998</pub-id><pub-id pub-id-type="pmcid">PMC2849637</pub-id></element-citation></ref><ref id="B15-nutrients-17-02813"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liberti</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Locasale</surname><given-names>J.W.</given-names></name></person-group><article-title>The Warburg effect: How does it benefit cancer cells?</article-title><source>Trends Biochem. Sci.</source><year>2016</year><volume>41</volume><fpage>211</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2015.12.001</pub-id><pub-id pub-id-type="pmid">26778478</pub-id><pub-id pub-id-type="pmcid">PMC4783224</pub-id></element-citation></ref><ref id="B16-nutrients-17-02813"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name></person-group><article-title>Amino acid metabolism in tumor biology and therapy</article-title><source>Cell Death Dis.</source><year>2024</year><volume>15</volume><fpage>42</fpage><pub-id pub-id-type="doi">10.1038/s41419-024-06435-w</pub-id><pub-id pub-id-type="pmid">38218942</pub-id><pub-id pub-id-type="pmcid">PMC10787762</pub-id></element-citation></ref><ref id="B17-nutrients-17-02813"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Locasale</surname><given-names>J.W.</given-names></name></person-group><article-title>Serine, glycine and one-carbon units: Cancer metabolism in full circle</article-title><source>Nat. Rev. Cancer</source><year>2013</year><volume>13</volume><fpage>572</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1038/nrc3557</pub-id><pub-id pub-id-type="pmid">23822983</pub-id><pub-id pub-id-type="pmcid">PMC3806315</pub-id></element-citation></ref><ref id="B18-nutrients-17-02813"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Baba</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>I.R.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Husain</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Haris</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Akil</surname><given-names>A.S.A.</given-names></name><name name-style="western"><surname>Macha</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>Glutamine Metabolism: Molecular Regulation, Biological Functions, and Diseases</article-title><source>MedComm</source><year>2025</year><volume>6</volume><fpage>e70120</fpage><pub-id pub-id-type="doi">10.1002/mco2.70120</pub-id><pub-id pub-id-type="pmid">40567251</pub-id><pub-id pub-id-type="pmcid">PMC12188105</pub-id></element-citation></ref><ref id="B19-nutrients-17-02813"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mider</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Tesluk</surname><given-names>H.</given-names></name><name name-style="western"><surname>Morton</surname><given-names>J.J.</given-names></name></person-group><article-title>Effects of Walker carcinoma 256 on food intake, body weight and nitrogen metabolism of growing rats</article-title><source>Acta Union. Int. Contra Cancrum</source><year>1948</year><volume>6</volume><fpage>409</fpage><lpage>420</lpage></element-citation></ref><ref id="B20-nutrients-17-02813"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Babson</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Winnick</surname><given-names>T.</given-names></name></person-group><article-title>Protein transfer in tumor-bearing rats</article-title><source>Cancer Res.</source><year>1954</year><volume>14</volume><fpage>606</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">13199806</pub-id></element-citation></ref><ref id="B21-nutrients-17-02813"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stehle</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sinn</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wunder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schrenk</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>J.C.M.</given-names></name><name name-style="western"><surname>Hartung</surname><given-names>G.</given-names></name><name name-style="western"><surname>Maier-Borst</surname><given-names>W.</given-names></name><name name-style="western"><surname>Heene</surname><given-names>D.L.</given-names></name></person-group><article-title>Plasma protein (albumin) catabolism by the tumor itself&#8212;Implications for tumor metabolism and the genesis of cachexia</article-title><source>Crit. Rev. Oncol. Hematol.</source><year>1997</year><volume>26</volume><fpage>77</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/S1040-8428(97)00015-2</pub-id><pub-id pub-id-type="pmid">9298326</pub-id></element-citation></ref><ref id="B22-nutrients-17-02813"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanahan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Weinberg</surname><given-names>R.A.</given-names></name></person-group><article-title>Hallmarks of cancer: The next generation</article-title><source>Cell</source><year>2011</year><volume>144</volume><fpage>646</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="B23-nutrients-17-02813"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wetzel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tenner</surname><given-names>B.</given-names></name><name name-style="western"><surname>D&#8217;Andrea</surname><given-names>L.</given-names></name></person-group><article-title>Crosstalk between arginine, glutamine, and branched-chain amino acid metabolism in the tumor microenvironment</article-title><source>Trends Cancer</source><year>2023</year><volume>9</volume><fpage>589</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.3389/fonc.2023.1186539</pub-id><pub-id pub-id-type="pmcid">PMC10235471</pub-id><pub-id pub-id-type="pmid">37274280</pub-id></element-citation></ref><ref id="B24-nutrients-17-02813"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wi&#223;feld</surname><given-names>J.</given-names></name><name name-style="western"><surname>Werner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ten Bosch</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>G.</given-names></name></person-group><article-title>Metabolic regulation of immune responses to cancer</article-title><source>Cancer Biol. Med.</source><year>2022</year><volume>19</volume><fpage>1528</fpage><lpage>1542</lpage><pub-id pub-id-type="doi">10.20892/j.issn.2095-3941.2022.0381</pub-id><pub-id pub-id-type="pmid">36269001</pub-id><pub-id pub-id-type="pmcid">PMC9724228</pub-id></element-citation></ref><ref id="B25-nutrients-17-02813"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>Metabolic reprogramming and immune evasion in cancer: The role of glutamine metabolism</article-title><source>Biomark. Res.</source><year>2024</year><volume>12</volume><elocation-id>25</elocation-id><pub-id pub-id-type="doi">10.1186/s40364-024-00646-1</pub-id><pub-id pub-id-type="pmid">39227970</pub-id><pub-id pub-id-type="pmcid">PMC11373140</pub-id></element-citation></ref><ref id="B26-nutrients-17-02813"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name></person-group><article-title>Glutamine and cancer: Metabolism, immune microenvironment, and therapeutic targets</article-title><source>Cell Commun. Signal.</source><year>2025</year><volume>23</volume><fpage>45</fpage><pub-id pub-id-type="doi">10.1186/s12964-024-02018-6</pub-id><pub-id pub-id-type="pmid">39856712</pub-id><pub-id pub-id-type="pmcid">PMC11760113</pub-id></element-citation></ref><ref id="B27-nutrients-17-02813"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lemos</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Prendergast</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Mellor</surname><given-names>A.L.</given-names></name></person-group><article-title>Immune control by amino acid catabolism during tumorigenesis and therapy</article-title><source>Nat. Rev. Cancer</source><year>2019</year><volume>19</volume><fpage>162</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1038/s41568-019-0106-z</pub-id><pub-id pub-id-type="pmid">30696923</pub-id></element-citation></ref><ref id="B28-nutrients-17-02813"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Burkhardt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gross</surname><given-names>C.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>J.S.</given-names></name></person-group><article-title>Quantifying absolute protein synthesis rates reveals principles underlying allocation of cellular resources</article-title><source>Cell</source><year>2014</year><volume>157</volume><fpage>624</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.02.033</pub-id><pub-id pub-id-type="pmid">24766808</pub-id><pub-id pub-id-type="pmcid">PMC4006352</pub-id></element-citation></ref><ref id="B29-nutrients-17-02813"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vasan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Werner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chandel</surname><given-names>N.S.</given-names></name></person-group><article-title>Mitochondrial metabolism as a target for cancer therapy</article-title><source>Cell Metab.</source><year>2020</year><volume>32</volume><fpage>341</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2020.06.019</pub-id><pub-id pub-id-type="pmid">32668195</pub-id><pub-id pub-id-type="pmcid">PMC7483781</pub-id></element-citation></ref><ref id="B30-nutrients-17-02813"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corn</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Windham</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Rafat</surname><given-names>M.</given-names></name></person-group><article-title>Lipids in the tumor microenvironment: From cancer progression to treatment</article-title><source>Prog. Lipid Res.</source><year>2020</year><volume>80</volume><fpage>101055</fpage><pub-id pub-id-type="doi">10.1016/j.plipres.2020.101055</pub-id><pub-id pub-id-type="pmid">32791170</pub-id><pub-id pub-id-type="pmcid">PMC7674189</pub-id></element-citation></ref><ref id="B31-nutrients-17-02813"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vriens</surname><given-names>K.</given-names></name><name name-style="western"><surname>Christen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Parik</surname><given-names>S.</given-names></name><name name-style="western"><surname>Broekaert</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yoshinaga</surname><given-names>K.</given-names></name><name name-style="western"><surname>Talebi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dehairs</surname><given-names>J.</given-names></name><name name-style="western"><surname>Escalona-Noguero</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schmieder</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cornfield</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Evidence for an alternative fatty acid desaturation pathway increasing cancer</article-title><source>Nature</source><year>2019</year><volume>566</volume><fpage>403</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-0904-1</pub-id><pub-id pub-id-type="pmid">30728499</pub-id><pub-id pub-id-type="pmcid">PMC6390935</pub-id></element-citation></ref><ref id="B32-nutrients-17-02813"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peck</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>A.</given-names></name></person-group><article-title>Lipid desaturation&#8212;The next step in targeting lipogenesis in cancer?</article-title><source>FEBS J.</source><year>2016</year><volume>283</volume><fpage>2767</fpage><lpage>2778</lpage><pub-id pub-id-type="doi">10.1111/febs.13681</pub-id><pub-id pub-id-type="pmid">26881388</pub-id></element-citation></ref><ref id="B33-nutrients-17-02813"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonfili</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cecarini</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cuccioloni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Angeletti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Flati</surname><given-names>V.</given-names></name><name name-style="western"><surname>Corsetti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pasini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dioguardi</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Eleuteri</surname><given-names>A.M.</given-names></name></person-group><article-title>Essential amino acid mixtures drive cancer cells to apoptosis through proteasome inhibition and autophagy activation</article-title><source>FEBS J.</source><year>2017</year><volume>284</volume><fpage>1726</fpage><lpage>1737</lpage><pub-id pub-id-type="doi">10.1111/febs.14081</pub-id><pub-id pub-id-type="pmid">28391610</pub-id></element-citation></ref><ref id="B34-nutrients-17-02813"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ragni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fornelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nisoli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Penna</surname><given-names>F.</given-names></name></person-group><article-title>Amino acids in cancer and cachexia: An integrated view</article-title><source>Cancers</source><year>2022</year><volume>14</volume><elocation-id>5691</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14225691</pub-id><pub-id pub-id-type="pmid">36428783</pub-id><pub-id pub-id-type="pmcid">PMC9688864</pub-id></element-citation></ref><ref id="B35-nutrients-17-02813"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corsetti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Romano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Codenotti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Giugno</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pasini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fanzani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scarabelli</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dioguardi</surname><given-names>F.S.</given-names></name></person-group><article-title>Intake of special amino acids mixture leads to blunted murine colon cancer growth in vitro and in vivo</article-title><source>Cells</source><year>2024</year><volume>13</volume><elocation-id>1210</elocation-id><pub-id pub-id-type="doi">10.3390/cells13141210</pub-id><pub-id pub-id-type="pmid">39056792</pub-id><pub-id pub-id-type="pmcid">PMC11274386</pub-id></element-citation></ref><ref id="B36-nutrients-17-02813"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akbay</surname><given-names>B.</given-names></name><name name-style="western"><surname>Omarova</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Trofimov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sailike</surname><given-names>B.</given-names></name><name name-style="western"><surname>Karapina</surname><given-names>O.</given-names></name><name name-style="western"><surname>Moln&#225;r</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tokay</surname><given-names>T.</given-names></name></person-group><article-title>Double-edge effects of leucine on cancer cells</article-title><source>Biomolecules</source><year>2024</year><volume>14</volume><elocation-id>1401</elocation-id><pub-id pub-id-type="doi">10.3390/biom14111401</pub-id><pub-id pub-id-type="pmid">39595578</pub-id><pub-id pub-id-type="pmcid">PMC11591885</pub-id></element-citation></ref><ref id="B37-nutrients-17-02813"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deldicque</surname><given-names>L.</given-names></name><name name-style="western"><surname>Theisen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Francaux</surname><given-names>M.</given-names></name></person-group><article-title>Regulation of mTOR by amino acids and resistance exercise in skeletal muscle</article-title><source>Eur. J. Appl. Physiol.</source><year>2005</year><volume>94</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/s00421-004-1255-6</pub-id><pub-id pub-id-type="pmid">15702344</pub-id></element-citation></ref><ref id="B38-nutrients-17-02813"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name></person-group><article-title>mTOR signaling pathway and mTOR inhibitors in cancer: Progress and challenges</article-title><source>Cell Biosci.</source><year>2020</year><volume>10</volume><elocation-id>31</elocation-id><pub-id pub-id-type="doi">10.1186/s13578-020-00396-1</pub-id><pub-id pub-id-type="pmid">32175074</pub-id><pub-id pub-id-type="pmcid">PMC7063815</pub-id></element-citation></ref><ref id="B39-nutrients-17-02813"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guertin</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Sabatini</surname><given-names>D.M.</given-names></name></person-group><article-title>Defining the role of mTOR in cancer</article-title><source>Cancer Cell</source><year>2007</year><volume>12</volume><fpage>9</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2007.05.008</pub-id><pub-id pub-id-type="pmid">17613433</pub-id></element-citation></ref><ref id="B40-nutrients-17-02813"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuzick</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thorat</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Andriole</surname><given-names>G.</given-names></name><name name-style="western"><surname>Brawley</surname><given-names>O.W.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Culig</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Eeles</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Ford</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Hamdy</surname><given-names>F.</given-names></name><name name-style="western"><surname>Holmberg</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Prevention and early detection of prostate cancer</article-title><source>Lancet Oncol.</source><year>2014</year><volume>15</volume><fpage>e484</fpage><lpage>e492</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)70211-6</pub-id><pub-id pub-id-type="pmid">25281467</pub-id><pub-id pub-id-type="pmcid">PMC4203149</pub-id></element-citation></ref><ref id="B41-nutrients-17-02813"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Garcia-Closas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gescher</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Key</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Saxton</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Harvie</surname><given-names>M.N.</given-names></name></person-group><article-title>Risk determination and prevention of breast cancer</article-title><source>Breast Cancer Res.</source><year>2014</year><volume>16</volume><fpage>446</fpage><pub-id pub-id-type="doi">10.1186/s13058-014-0446-2</pub-id><pub-id pub-id-type="pmid">25467785</pub-id><pub-id pub-id-type="pmcid">PMC4303126</pub-id></element-citation></ref><ref id="B42-nutrients-17-02813"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Courneya</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Mackey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gelmon</surname><given-names>K.</given-names></name><name name-style="western"><surname>Friedenreich</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Yasui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Vallerand</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Proulx</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapy</article-title><source>Br. J. Cancer</source><year>2014</year><volume>111</volume><fpage>1718</fpage><lpage>1725</lpage><pub-id pub-id-type="doi">10.1038/bjc.2014.466</pub-id><pub-id pub-id-type="pmid">25144625</pub-id><pub-id pub-id-type="pmcid">PMC4453726</pub-id></element-citation></ref><ref id="B43-nutrients-17-02813"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avruch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Long</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ortiz-Vega</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rapley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Papageorgiou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>N.</given-names></name></person-group><article-title>Amino acid regulation of TOR complex 1</article-title><source>Am. J. Physiol. Endocrinol. Metab.</source><year>2009</year><volume>296</volume><fpage>E592</fpage><lpage>E602</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.90645.2008</pub-id><pub-id pub-id-type="pmid">18765678</pub-id><pub-id pub-id-type="pmcid">PMC2670622</pub-id></element-citation></ref><ref id="B44-nutrients-17-02813"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicklin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bergman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Triantafellow</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nyfeler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hild</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kung</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Bidirectional transport of amino acids regulates mTOR and autophagy</article-title><source>Cell</source><year>2009</year><volume>136</volume><fpage>521</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.11.044</pub-id><pub-id pub-id-type="pmid">19203585</pub-id><pub-id pub-id-type="pmcid">PMC3733119</pub-id></element-citation></ref><ref id="B45-nutrients-17-02813"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flati</surname><given-names>V.</given-names></name><name name-style="western"><surname>Corsetti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pasini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rufo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Romano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dioguardi</surname><given-names>F.S.</given-names></name></person-group><article-title>Nutrition, nitrogen requirements, exercise and chemotherapy-induced toxicity in cancer patients. a puzzle of contrasting truths?</article-title><source>Anticancer. Agents Med. Chem.</source><year>2016</year><volume>16</volume><fpage>89</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.2174/1871520615666150824152900</pub-id><pub-id pub-id-type="pmid">26299664</pub-id></element-citation></ref><ref id="B46-nutrients-17-02813"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanarek</surname><given-names>N.</given-names></name><name name-style="western"><surname>Petrova</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sabatini</surname><given-names>D.M.</given-names></name></person-group><article-title>Dietary modifications for enhanced cancer therapy</article-title><source>Nature</source><year>2020</year><volume>579</volume><fpage>507</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2124-0</pub-id><pub-id pub-id-type="pmid">32214253</pub-id></element-citation></ref><ref id="B47-nutrients-17-02813"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>P.</given-names></name></person-group><article-title>Metabolism of amino acids in cancer</article-title><source>Front. Cell Dev. Biol.</source><year>2021</year><volume>8</volume><elocation-id>603837</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2020.603837</pub-id><pub-id pub-id-type="pmid">33511116</pub-id><pub-id pub-id-type="pmcid">PMC7835483</pub-id></element-citation></ref><ref id="B48-nutrients-17-02813"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name></person-group><article-title>Amino acids: Metabolism, functions, and nutrition</article-title><source>Amino Acids</source><year>2009</year><volume>37</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1007/s00726-009-0269-0</pub-id><pub-id pub-id-type="pmid">19301095</pub-id></element-citation></ref><ref id="B49-nutrients-17-02813"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherman</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Morton</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Mider</surname><given-names>G.B.</given-names></name></person-group><article-title>Potential sources of tumor nitrogen</article-title><source>Cancer Res.</source><year>1950</year><volume>10</volume><fpage>374</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">15420707</pub-id></element-citation></ref><ref id="B50-nutrients-17-02813"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eagle</surname><given-names>H.</given-names></name></person-group><article-title>The specific amino acid requirements of a human carcinoma cell (Stain HeLa) in tissue culture</article-title><source>J. Exp. Med.</source><year>1955</year><volume>102</volume><fpage>37</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1084/jem.102.1.37</pub-id><pub-id pub-id-type="pmid">14392239</pub-id><pub-id pub-id-type="pmcid">PMC2136494</pub-id></element-citation></ref><ref id="B51-nutrients-17-02813"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allison</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Wannemacher</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Prosky</surname><given-names>L.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Crossley</surname><given-names>M.L.</given-names></name></person-group><article-title>Nutritive value of protein and tumor-host relationship in the rat</article-title><source>J. Nutr.</source><year>1956</year><volume>60</volume><fpage>297</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1093/jn/60.2.297</pub-id><pub-id pub-id-type="pmid">13367913</pub-id></element-citation></ref><ref id="B52-nutrients-17-02813"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Bier</surname><given-names>D.M.</given-names></name></person-group><article-title>Amino acid requirements in adult humans: How well do we know them?</article-title><source>J. Nutr.</source><year>1987</year><volume>117</volume><fpage>1484</fpage><lpage>1487</lpage><pub-id pub-id-type="doi">10.1093/jn/117.8.1484</pub-id><pub-id pub-id-type="pmid">3305816</pub-id></element-citation></ref><ref id="B53-nutrients-17-02813"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Menon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bernfeld</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mroz</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kalan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Loayza</surname><given-names>D.</given-names></name><name name-style="western"><surname>Foster</surname><given-names>D.A.</given-names></name></person-group><article-title>Aspartate rescuess-phase arrest caused by suppression of glutamine utilization in KR as driven cancer cells</article-title><source>J. Biol. Chem.</source><year>2016</year><volume>291</volume><fpage>9322</fpage><lpage>9939</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.710145</pub-id><pub-id pub-id-type="pmid">26921316</pub-id><pub-id pub-id-type="pmcid">PMC4861495</pub-id></element-citation></ref><ref id="B54-nutrients-17-02813"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cruzat</surname><given-names>V.</given-names></name><name name-style="western"><surname>Macedo Rogero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Noel Keane</surname><given-names>K.</given-names></name><name name-style="western"><surname>Curi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Newsholme</surname><given-names>P.</given-names></name></person-group><article-title>Glutamine: Metabolism and immune function, supplementation and clinical translation</article-title><source>Nutrients</source><year>2018</year><volume>10</volume><elocation-id>1564</elocation-id><pub-id pub-id-type="doi">10.3390/nu10111564</pub-id><pub-id pub-id-type="pmid">30360490</pub-id><pub-id pub-id-type="pmcid">PMC6266414</pub-id></element-citation></ref><ref id="B55-nutrients-17-02813"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cluntun</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Lukey</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Cerione</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Locasale</surname><given-names>J.W.</given-names></name></person-group><article-title>Glutamine metabolism in cancer: Understanding the heterogeneity</article-title><source>Trends Cancer</source><year>2017</year><volume>3</volume><fpage>169</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2017.01.005</pub-id><pub-id pub-id-type="pmid">28393116</pub-id><pub-id pub-id-type="pmcid">PMC5383348</pub-id></element-citation></ref><ref id="B56-nutrients-17-02813"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reitzer</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Wice</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Kennell</surname><given-names>D.</given-names></name></person-group><article-title>Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells</article-title><source>J. Biol. Chem.</source><year>1979</year><volume>254</volume><fpage>2669</fpage><lpage>2676</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(17)30124-2</pub-id><pub-id pub-id-type="pmid">429309</pub-id></element-citation></ref><ref id="B57-nutrients-17-02813"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W.</given-names></name></person-group><article-title>AMPK as a metabolic tumor suppressor: Control of metabolism and cell growth</article-title><source>Future Oncol.</source><year>2010</year><volume>6</volume><fpage>457</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.2217/fon.09.174</pub-id><pub-id pub-id-type="pmid">20222801</pub-id><pub-id pub-id-type="pmcid">PMC2854547</pub-id></element-citation></ref><ref id="B58-nutrients-17-02813"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villar</surname><given-names>V.H.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Ter&#233;s</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bodineau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dur&#225;n</surname><given-names>R.V.</given-names></name></person-group><article-title>Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR</article-title><source>Mol. Cell Oncol.</source><year>2017</year><volume>4</volume><fpage>e1297284</fpage><pub-id pub-id-type="doi">10.1080/23723556.2017.1297284</pub-id><pub-id pub-id-type="pmid">28616576</pub-id><pub-id pub-id-type="pmcid">PMC5462510</pub-id></element-citation></ref><ref id="B59-nutrients-17-02813"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bodineau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tom&#233;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Courtois</surname><given-names>S.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>A.S.H.</given-names></name><name name-style="western"><surname>Sciacovelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rousseau</surname><given-names>B.</given-names></name><name name-style="western"><surname>Richard</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vacher</surname><given-names>P.</given-names></name><name name-style="western"><surname>Parejo-P&#233;rez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bessede</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Two parallel pathways connect glutamine metabolism and mTORC1 activity to regulate glutamoptosis</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>4814</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-25079-4</pub-id><pub-id pub-id-type="pmid">34376668</pub-id><pub-id pub-id-type="pmcid">PMC8355106</pub-id></element-citation></ref><ref id="B60-nutrients-17-02813"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krall</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Graeber</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Braas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Christofk</surname><given-names>H.R.</given-names></name></person-group><article-title>Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>11457</fpage><pub-id pub-id-type="doi">10.1038/ncomms11457</pub-id><pub-id pub-id-type="pmid">27126896</pub-id><pub-id pub-id-type="pmcid">PMC4855534</pub-id></element-citation></ref><ref id="B61-nutrients-17-02813"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Termini</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wilczynski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vaidehi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Choy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kowolik</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hambrecht</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jandial</surname><given-names>R.</given-names></name></person-group><article-title>Human breast cancer metastases to the brain display GABAergic properties in the neural niche</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>984</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1073/pnas.1322098111</pub-id><pub-id pub-id-type="pmid">24395782</pub-id><pub-id pub-id-type="pmcid">PMC3903266</pub-id></element-citation></ref><ref id="B62-nutrients-17-02813"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bodineau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tom&#233;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Murdoch</surname><given-names>P.D.S.</given-names></name><name name-style="western"><surname>Dur&#225;n</surname><given-names>R.V.</given-names></name></person-group><article-title>Glutamine, MTOR and autophagy: A multiconnection relationship</article-title><source>Autophagy</source><year>2022</year><volume>18</volume><fpage>2749</fpage><lpage>2750</lpage><pub-id pub-id-type="doi">10.1080/15548627.2022.2062875</pub-id><pub-id pub-id-type="pmid">35470752</pub-id><pub-id pub-id-type="pmcid">PMC9629096</pub-id></element-citation></ref><ref id="B63-nutrients-17-02813"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sener</surname><given-names>A.</given-names></name><name name-style="western"><surname>Malaisse</surname><given-names>W.J.</given-names></name></person-group><article-title>L-leucine and a nonmetabolized analogue activate pancreatic islet glutamate dehydrogenase</article-title><source>Nature</source><year>1980</year><volume>288</volume><fpage>187</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1038/288187a0</pub-id><pub-id pub-id-type="pmid">7001252</pub-id></element-citation></ref><ref id="B64-nutrients-17-02813"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tennant</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>E.</given-names></name></person-group><article-title>HIF prolyl hydroxylase-3 mediates alpha-ketoglutarate-induced apoptosis and tumor suppression</article-title><source>J. Mol. Med.</source><year>2010</year><volume>88</volume><fpage>839</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1007/s00109-010-0627-0</pub-id><pub-id pub-id-type="pmid">20383689</pub-id></element-citation></ref><ref id="B65-nutrients-17-02813"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howell</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Ricoult</surname><given-names>S.J.H.</given-names></name><name name-style="western"><surname>Ben-Sahra</surname><given-names>I.</given-names></name><name name-style="western"><surname>Manning</surname><given-names>B.D.</given-names></name></person-group><article-title>A growing role for mTOR in promoting anabolic metabolism</article-title><source>Biochem. Soc. Trans.</source><year>2013</year><volume>41</volume><fpage>906</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1042/BST20130041</pub-id><pub-id pub-id-type="pmid">23863154</pub-id></element-citation></ref><ref id="B66-nutrients-17-02813"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villar</surname><given-names>V.H.</given-names></name><name name-style="western"><surname>Merhi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Djavaheri-Mergny</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dur&#225;n</surname><given-names>R.V.</given-names></name></person-group><article-title>Glutaminolysis and autophagy in cancer</article-title><source>Autophagy</source><year>2015</year><volume>11</volume><fpage>1198</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1080/15548627.2015.1053680</pub-id><pub-id pub-id-type="pmid">26054373</pub-id><pub-id pub-id-type="pmcid">PMC4590661</pub-id></element-citation></ref><ref id="B67-nutrients-17-02813"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mikaelian</surname><given-names>I.</given-names></name><name name-style="western"><surname>Malek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gadet</surname><given-names>R.</given-names></name><name name-style="western"><surname>Viallet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Girard-Gagnepain</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hesling</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gillet</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gonzalo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rimokh</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Genetic and pharmacologic inhibition of mTORC1 promotes EMT by a TGF-&#946;-independent mechanism</article-title><source>Cancer Res.</source><year>2013</year><volume>73</volume><fpage>6621</fpage><lpage>6631</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-0560</pub-id><pub-id pub-id-type="pmid">24078802</pub-id></element-citation></ref><ref id="B68-nutrients-17-02813"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jim&#233;nez-Alonso</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>L&#243;pez-L&#225;zaro</surname><given-names>M.</given-names></name></person-group><article-title>Dietary Manipulation of Amino Acids for Cancer Therapy</article-title><source>Nutrients</source><year>2023</year><volume>15</volume><elocation-id>2879</elocation-id><pub-id pub-id-type="doi">10.3390/nu15132879</pub-id><pub-id pub-id-type="pmid">37447206</pub-id><pub-id pub-id-type="pmcid">PMC10346484</pub-id></element-citation></ref><ref id="B69-nutrients-17-02813"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Lashinger</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Hursting</surname><given-names>S.D.</given-names></name></person-group><article-title>Leucine Supplementation Differentially Enhances Pancreatic Cancer Growth in Lean and Overweight Mice</article-title><source>Cancer Metab.</source><year>2014</year><volume>2</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/2049-3002-2-6</pub-id><pub-id pub-id-type="pmid">24685128</pub-id><pub-id pub-id-type="pmcid">PMC4392529</pub-id></element-citation></ref><ref id="B70-nutrients-17-02813"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Reiche</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Fifelski</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Stanford</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Nack</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Radlwimmer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Ananieva</surname><given-names>E.A.</given-names></name></person-group><article-title>Leucine and branched-chain amino acid metabolism contribute to the growth of bone sarcomas by regulating AMPK and mTORC1 signaling</article-title><source>Biochem. J.</source><year>2020</year><volume>477</volume><fpage>1579</fpage><lpage>1599</lpage><pub-id pub-id-type="doi">10.1042/BCJ20190754</pub-id><pub-id pub-id-type="pmid">32297642</pub-id></element-citation></ref><ref id="B71-nutrients-17-02813"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassan</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Helmy</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Ghoneim</surname><given-names>A.I.</given-names></name></person-group><article-title>Combinatorial antitumor effects of amino acids and epigenetic modulations in hepatocellular carcinoma cell lines</article-title><source>Naunyn Schmiedebergs Arch. Pharmacol.</source><year>2021</year><volume>394</volume><fpage>2245</fpage><lpage>2257</lpage><pub-id pub-id-type="doi">10.1007/s00210-021-02140-z</pub-id><pub-id pub-id-type="pmid">34415354</pub-id></element-citation></ref><ref id="B72-nutrients-17-02813"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hosios</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Hecht</surname><given-names>V.C.</given-names></name><name name-style="western"><surname>Danai</surname><given-names>L.V.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Rathmell</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Steinhauser</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Manalis</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Vander Heiden</surname><given-names>M.G.</given-names></name></person-group><article-title>Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells</article-title><source>Dev. Cell</source><year>2016</year><volume>36</volume><fpage>540</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2016.02.012</pub-id><pub-id pub-id-type="pmid">26954548</pub-id><pub-id pub-id-type="pmcid">PMC4766004</pub-id></element-citation></ref><ref id="B73-nutrients-17-02813"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>J.S.</given-names></name></person-group><article-title>Dietary restriction of amino acids for cancer therapy</article-title><source>Nutr. Metab.</source><year>2020</year><volume>17</volume><fpage>20</fpage><pub-id pub-id-type="doi">10.1186/s12986-020-00439-x</pub-id><pub-id pub-id-type="pmcid">PMC7071719</pub-id><pub-id pub-id-type="pmid">32190097</pub-id></element-citation></ref><ref id="B74-nutrients-17-02813"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>E.</given-names></name></person-group><article-title>Targeting serine-glycine-one-carbon metabolism as a vulnerability in cancers</article-title><source>Biomark. Res.</source><year>2023</year><volume>11</volume><elocation-id>48</elocation-id><pub-id pub-id-type="doi">10.1186/s40364-023-00487-4</pub-id><pub-id pub-id-type="pmid">37147729</pub-id><pub-id pub-id-type="pmcid">PMC10161514</pub-id></element-citation></ref><ref id="B75-nutrients-17-02813"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newman</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Maddocks</surname><given-names>O.D.K.</given-names></name></person-group><article-title>Serine and functional metabolites in cancer</article-title><source>Trends Cell Biol.</source><year>2017</year><volume>27</volume><fpage>645</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2017.05.001</pub-id><pub-id pub-id-type="pmid">28601431</pub-id></element-citation></ref><ref id="B76-nutrients-17-02813"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Madhusudhan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kitami</surname><given-names>T.</given-names></name><name name-style="western"><surname>Souza</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Kafri</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kirschner</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Clish</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Mootha</surname><given-names>V.K.</given-names></name></person-group><article-title>Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation</article-title><source>Science</source><year>2012</year><volume>336</volume><fpage>1040</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1126/science.1218595</pub-id><pub-id pub-id-type="pmid">22628656</pub-id><pub-id pub-id-type="pmcid">PMC3526189</pub-id></element-citation></ref><ref id="B77-nutrients-17-02813"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Itoyama</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yasuda-Yoshihara</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kitamura</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yasuda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yonemura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Uchihara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Arima</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jun</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Metabolic shift to serine biosynthesis through 3-PG accumulation and PHGDH induction promotes tumor growth in pancreatic cancer</article-title><source>Cancer Lett.</source><year>2021</year><volume>523</volume><fpage>29</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2021.09.007</pub-id><pub-id pub-id-type="pmid">34508795</pub-id></element-citation></ref><ref id="B78-nutrients-17-02813"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geeraerts</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Heylen</surname><given-names>E.</given-names></name><name name-style="western"><surname>De Keersmaecker</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kampen</surname><given-names>K.R.</given-names></name></person-group><article-title>The ins and outs of serine and glycine metabolism in cancer</article-title><source>Nat. Metab.</source><year>2021</year><volume>3</volume><fpage>131</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1038/s42255-020-00329-9</pub-id><pub-id pub-id-type="pmid">33510397</pub-id></element-citation></ref><ref id="B79-nutrients-17-02813"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gracilla</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Long</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>C.</given-names></name></person-group><article-title>ATF3 promotes the serine synthesis pathway and tumor growth under dietary serine restriction</article-title><source>Cell Rep.</source><year>2021</year><volume>36</volume><fpage>109706</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109706</pub-id><pub-id pub-id-type="pmid">34551291</pub-id><pub-id pub-id-type="pmcid">PMC8491098</pub-id></element-citation></ref><ref id="B80-nutrients-17-02813"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Ann</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kung</surname><given-names>H.J.</given-names></name></person-group><article-title>Arginine Signaling and Cancer Metabolism</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>3541</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13143541</pub-id><pub-id pub-id-type="pmid">34298755</pub-id><pub-id pub-id-type="pmcid">PMC8306961</pub-id></element-citation></ref><ref id="B81-nutrients-17-02813"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delage</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fennell</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Nicholson</surname><given-names>L.</given-names></name><name name-style="western"><surname>McNeish</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lemoine</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Crook</surname><given-names>T.</given-names></name><name name-style="western"><surname>Szlosarek</surname><given-names>P.W.</given-names></name></person-group><article-title>Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer</article-title><source>Int. J. Cancer</source><year>2010</year><volume>126</volume><fpage>2762</fpage><lpage>2772</lpage><pub-id pub-id-type="doi">10.1002/ijc.25202</pub-id><pub-id pub-id-type="pmid">20104527</pub-id></element-citation></ref><ref id="B82-nutrients-17-02813"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marigo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Dolcetti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Serafini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zanovello</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bronte</surname><given-names>V.</given-names></name></person-group><article-title>Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells</article-title><source>Immunol. Rev.</source><year>2008</year><volume>222</volume><fpage>162</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2008.00602.x</pub-id><pub-id pub-id-type="pmid">18364001</pub-id></element-citation></ref><ref id="B83-nutrients-17-02813"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lyu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fai To</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>W.</given-names></name></person-group><article-title>The arginine metabolism and its deprivation in cancer therapy</article-title><source>Cancer Lett.</source><year>2025</year><volume>620</volume><fpage>217680</fpage><pub-id pub-id-type="doi">10.1016/j.canlet.2025.217680</pub-id><pub-id pub-id-type="pmid">40157492</pub-id></element-citation></ref><ref id="B84-nutrients-17-02813"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>L.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zu</surname><given-names>X.</given-names></name></person-group><article-title>Metabolism of asparagine in the physiological state and cancer</article-title><source>Cell Commun. Signal.</source><year>2024</year><volume>22</volume><fpage>163</fpage><pub-id pub-id-type="doi">10.1186/s12964-024-01540-x</pub-id><pub-id pub-id-type="pmid">38448969</pub-id><pub-id pub-id-type="pmcid">PMC10916255</pub-id></element-citation></ref><ref id="B85-nutrients-17-02813"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knott</surname><given-names>S.R.V.</given-names></name><name name-style="western"><surname>Wagenblast</surname><given-names>E.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Soto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Turgeon</surname><given-names>M.-O.</given-names></name><name name-style="western"><surname>Fish</surname><given-names>L.</given-names></name><name name-style="western"><surname>Erard</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gable</surname><given-names>A.L.</given-names></name><etal/></person-group><article-title>Asparagine bioavailability governs metastasis in a model of breast cancer</article-title><source>Nature</source><year>2018</year><volume>554</volume><fpage>378</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1038/nature25465</pub-id><pub-id pub-id-type="pmid">29414946</pub-id><pub-id pub-id-type="pmcid">PMC5898613</pub-id></element-citation></ref><ref id="B86-nutrients-17-02813"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gajendran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ben-David</surname><given-names>Y.</given-names></name></person-group><article-title>Targeting pivotal amino acids metabolism for treatment of leukemia</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><fpage>e40492</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e40492</pub-id><pub-id pub-id-type="pmid">39654725</pub-id><pub-id pub-id-type="pmcid">PMC11626780</pub-id></element-citation></ref><ref id="B87-nutrients-17-02813"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pieters</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hunger</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Boos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rizzari</surname><given-names>C.</given-names></name><name name-style="western"><surname>Silverman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Baruchel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Goekbuget</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schrappe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pui</surname><given-names>C.H.</given-names></name></person-group><article-title>L-asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase</article-title><source>Cancer</source><year>2011</year><volume>117</volume><fpage>238</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1002/cncr.25489</pub-id><pub-id pub-id-type="pmid">20824725</pub-id><pub-id pub-id-type="pmcid">PMC3000881</pub-id></element-citation></ref><ref id="B88-nutrients-17-02813"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kawada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Obama</surname><given-names>K.</given-names></name></person-group><article-title>Targeting Asparagine Metabolism in Solid Tumors</article-title><source>Nutrients</source><year>2025</year><volume>17</volume><elocation-id>179</elocation-id><pub-id pub-id-type="doi">10.3390/nu17010179</pub-id><pub-id pub-id-type="pmid">39796613</pub-id><pub-id pub-id-type="pmcid">PMC11722615</pub-id></element-citation></ref><ref id="B89-nutrients-17-02813"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;Aniello</surname><given-names>C.</given-names></name><name name-style="western"><surname>Patriarca</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Phang</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Minchiotti</surname><given-names>G.</given-names></name></person-group><article-title>Proline metabolism in tumor growth and metastatic progression</article-title><source>Front. Oncol.</source><year>2020</year><volume>10</volume><elocation-id>776</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2020.00776</pub-id><pub-id pub-id-type="pmid">32500033</pub-id><pub-id pub-id-type="pmcid">PMC7243120</pub-id></element-citation></ref><ref id="B90-nutrients-17-02813"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amelio</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cutruzzol&#225;</surname><given-names>F.</given-names></name><name name-style="western"><surname>Antonov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agostini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Melino</surname><given-names>G.</given-names></name></person-group><article-title>Serine and glycine metabolism in cancer</article-title><source>Trends Biochem. Sci.</source><year>2014</year><volume>39</volume><fpage>191</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2014.02.004</pub-id><pub-id pub-id-type="pmid">24657017</pub-id><pub-id pub-id-type="pmcid">PMC3989988</pub-id></element-citation></ref><ref id="B91-nutrients-17-02813"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chenette</surname><given-names>E.</given-names></name></person-group><article-title>Glycine fuels cancer cells</article-title><source>Nat. Cell Biol.</source><year>2012</year><volume>14</volume><elocation-id>658</elocation-id><pub-id pub-id-type="doi">10.1038/ncb2542</pub-id></element-citation></ref><ref id="B92-nutrients-17-02813"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ericksen</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>McDonnell</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shuen</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Vadiveloo</surname><given-names>M.</given-names></name><name name-style="western"><surname>White</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Kwok</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>P.</given-names></name><name name-style="western"><surname>Radda</surname><given-names>G.K.</given-names></name><etal/></person-group><article-title>Loss of BCAA catabolism during carcinogenesis enhances mTORC1 activity and promotes tumor development and progression</article-title><source>Cell Metab.</source><year>2019</year><volume>29</volume><fpage>1151</fpage><lpage>1165.e6</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.12.020</pub-id><pub-id pub-id-type="pmid">30661928</pub-id><pub-id pub-id-type="pmcid">PMC6506390</pub-id></element-citation></ref><ref id="B93-nutrients-17-02813"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guri</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Colombi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dazert</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hindupur</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Roszik</surname><given-names>J.</given-names></name><name name-style="western"><surname>Moes</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jenoe</surname><given-names>P.</given-names></name><name name-style="western"><surname>Heim</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Riezman</surname><given-names>I.</given-names></name><name name-style="western"><surname>Riezman</surname><given-names>H.</given-names></name><etal/></person-group><article-title>mTORC2 promotes tumorigenesis via lipid synthesis</article-title><source>Cancer Cell</source><year>2017</year><volume>32</volume><fpage>807</fpage><lpage>823.e12</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.11.011</pub-id><pub-id pub-id-type="pmid">29232555</pub-id></element-citation></ref><ref id="B94-nutrients-17-02813"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butler</surname><given-names>M.</given-names></name><name name-style="western"><surname>van der Meer</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>van Leeuwen</surname><given-names>F.N.</given-names></name></person-group><article-title>Amino acid depletion therapies: Starving cancer cells to death</article-title><source>Trends Endocrinol. Metab.</source><year>2021</year><volume>32</volume><fpage>367</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2021.03.003</pub-id><pub-id pub-id-type="pmid">33795176</pub-id></element-citation></ref><ref id="B95-nutrients-17-02813"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kremer</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Prudner</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Lange</surname><given-names>S.E.S.</given-names></name><name name-style="western"><surname>Bean</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Schultze</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Brashears</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Radyk</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Redlich</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tzeng</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Kami</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Arginine deprivation inhibits the Warburg effect and upregulates glutamine anaplerosis and serine biosynthesis in ASS1-deficient cancers</article-title><source>Cell Rep.</source><year>2017</year><volume>18</volume><fpage>991</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.12.077</pub-id><pub-id pub-id-type="pmid">28122247</pub-id><pub-id pub-id-type="pmcid">PMC5840045</pub-id></element-citation></ref><ref id="B96-nutrients-17-02813"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dioguardi</surname><given-names>F.S.</given-names></name></person-group><article-title>Clinical use of amino acids as dietary supplement: Pros and cons</article-title><source>J. Cachexia Sarcopenia Muscle</source><year>2011</year><volume>2</volume><fpage>75</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1007/s13539-011-0032-8</pub-id><pub-id pub-id-type="pmid">21766052</pub-id><pub-id pub-id-type="pmcid">PMC3118002</pub-id></element-citation></ref><ref id="B97-nutrients-17-02813"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maddocks</surname><given-names>O.D.</given-names></name><name name-style="western"><surname>Berkers</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Blyth</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vousden</surname><given-names>K.H.</given-names></name></person-group><article-title>Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells</article-title><source>Nature</source><year>2013</year><volume>493</volume><fpage>542</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1038/nature11743</pub-id><pub-id pub-id-type="pmid">23242140</pub-id><pub-id pub-id-type="pmcid">PMC6485472</pub-id></element-citation></ref><ref id="B98-nutrients-17-02813"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>F.</given-names></name></person-group><article-title>Leucine deprivation inhibits proliferation and induces apoptosis of human breast cancer cells via fatty acid synthase</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>63679</fpage><lpage>63689</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.11626</pub-id><pub-id pub-id-type="pmid">27579768</pub-id><pub-id pub-id-type="pmcid">PMC5325395</pub-id></element-citation></ref><ref id="B99-nutrients-17-02813"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viana</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Tobar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Busanello</surname><given-names>E.N.B.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Lima</surname><given-names>T.I.</given-names></name><name name-style="western"><surname>Machado</surname><given-names>G.</given-names></name><name name-style="western"><surname>Castelucci</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Brunetto</surname><given-names>S.Q.</given-names></name><etal/></person-group><article-title>Leucine-rich diet induces a shift in tumour metabolism from glycolytic towards oxidative phosphorylation, reducing glucose consumption and metastasis in Walker-256 tumour-bearing rats</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><elocation-id>15529</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-52112-w</pub-id><pub-id pub-id-type="pmid">31664147</pub-id><pub-id pub-id-type="pmcid">PMC6820796</pub-id></element-citation></ref><ref id="B100-nutrients-17-02813"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>L.P.</given-names></name><etal/></person-group><article-title>BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma</article-title><source>Nat. Cell Biol.</source><year>2020</year><volume>22</volume><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1038/s41556-019-0455-6</pub-id><pub-id pub-id-type="pmid">32029896</pub-id></element-citation></ref><ref id="B101-nutrients-17-02813"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>Z.R.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Deficiency of BCAT2-mediated branched-chain amino acid catabolism promotes colorectal cancer development</article-title><source>Biochim. Biophys. Acta Mol. Basis Dis.</source><year>2024</year><volume>1870</volume><elocation-id>166941</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbadis.2023.166941</pub-id><pub-id pub-id-type="pmid">37926361</pub-id></element-citation></ref><ref id="B102-nutrients-17-02813"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jim&#233;nez-Alonso</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Guill&#233;n-Mancina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Calder&#243;n-Monta&#241;o</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Jim&#233;nez-Gonz&#225;lez</surname><given-names>V.</given-names></name><name name-style="western"><surname>D&#237;az-Ortega</surname><given-names>P.</given-names></name><name name-style="western"><surname>Burgos-Mor&#243;n</surname><given-names>E.</given-names></name><name name-style="western"><surname>L&#243;pez-L&#225;zaro</surname><given-names>M.</given-names></name></person-group><article-title>Artificial diets with altered levels of sulfur amino acids induce anticancer activity in mice with metastatic colon cancer, ovarian cancer and renal cell carcinoma</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>4587</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24054587</pub-id><pub-id pub-id-type="pmid">36902018</pub-id><pub-id pub-id-type="pmcid">PMC10003419</pub-id></element-citation></ref><ref id="B103-nutrients-17-02813"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dioguardi</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Flati</surname><given-names>V.</given-names></name><name name-style="western"><surname>Corsetti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pasini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Romano</surname><given-names>C.</given-names></name></person-group><article-title>Is the response of tumors dependent on the dietary input of some amino acids or ratios among essential and non-essential amino acids? All that glitters is not gold</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>3631</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19113631</pub-id><pub-id pub-id-type="pmid">30453654</pub-id><pub-id pub-id-type="pmcid">PMC6275049</pub-id></element-citation></ref><ref id="B104-nutrients-17-02813"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maddocks</surname><given-names>O.</given-names></name><name name-style="western"><surname>Athineos</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>van den Broek</surname><given-names>N.J.F.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Labuschagne</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Gay</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kruiswijk</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Correction: Corrigendum: Modulating the therapeutic response of tumors to dietary serine and glycine starvation</article-title><source>Nature</source><year>2017</year><volume>548</volume><fpage>122</fpage><pub-id pub-id-type="doi">10.1038/nature23471</pub-id><pub-id pub-id-type="pmid">28770843</pub-id></element-citation></ref><ref id="B105-nutrients-17-02813"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolfe</surname><given-names>R.R.</given-names></name></person-group><article-title>Branched-chain amino acids and muscle protein synthesis in humans: Myth or reality?</article-title><source>J. Int. Soc. Sports Nutr.</source><year>2017</year><volume>14</volume><fpage>30</fpage><pub-id pub-id-type="doi">10.1186/s12970-017-0184-9</pub-id><pub-id pub-id-type="pmid">28852372</pub-id><pub-id pub-id-type="pmcid">PMC5568273</pub-id></element-citation></ref><ref id="B106-nutrients-17-02813"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buyukgolcigezli</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tenekeci</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Sahin</surname><given-names>I.H.</given-names></name></person-group><article-title>Opportunities and challenges in antibody-drug conjugates for cancer therapy: A new era for cancer treatment</article-title><source>Cancers</source><year>2025</year><volume>17</volume><elocation-id>958</elocation-id><pub-id pub-id-type="doi">10.3390/cancers17060958</pub-id><pub-id pub-id-type="pmid">40149295</pub-id><pub-id pub-id-type="pmcid">PMC11939980</pub-id></element-citation></ref><ref id="B107-nutrients-17-02813"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corsetti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pasini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Scarabelli</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Romano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scarabelli</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Dioguardi</surname><given-names>F.S.</given-names></name></person-group><article-title>Importance of energy, dietary protein sources, and amino acid composition in the regulation of metabolism: An indissoluble dynamic combination for life</article-title><source>Nutrients</source><year>2024</year><volume>16</volume><elocation-id>2417</elocation-id><pub-id pub-id-type="doi">10.3390/nu16152417</pub-id><pub-id pub-id-type="pmid">39125298</pub-id><pub-id pub-id-type="pmcid">PMC11313897</pub-id></element-citation></ref><ref id="B108-nutrients-17-02813"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Corsetti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dioguardi</surname><given-names>F.S.</given-names></name></person-group><article-title>Behind protein synthesis: Amino acids-metabokine regulators of both systemic and cellular metabolism</article-title><source>Nutrients</source><year>2023</year><volume>15</volume><elocation-id>2892</elocation-id><pub-id pub-id-type="doi">10.3390/nu15132892</pub-id><pub-id pub-id-type="pmid">37447218</pub-id><pub-id pub-id-type="pmcid">PMC10346230</pub-id></element-citation></ref><ref id="B109-nutrients-17-02813"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krebs</surname><given-names>M.</given-names></name><name name-style="western"><surname>Krssak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bernroider</surname><given-names>E.</given-names></name><name name-style="western"><surname>Anderwald</surname><given-names>C.</given-names></name><name name-style="western"><surname>Brehm</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meyerspeer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nowotny</surname><given-names>P.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>E.</given-names></name><name name-style="western"><surname>Waldh&#228;usl</surname><given-names>W.</given-names></name><name name-style="western"><surname>Roden</surname><given-names>M.</given-names></name></person-group><article-title>Mechanism of amino acid-induced skeletal muscle insulin resistance in humans</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><fpage>599</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.2337/diabetes.51.3.599</pub-id><pub-id pub-id-type="pmid">11872656</pub-id></element-citation></ref><ref id="B110-nutrients-17-02813"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Corsetti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Flati</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pasini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Picca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Calvani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Marzetti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dioguardi</surname><given-names>F.S.</given-names></name></person-group><article-title>Influence of diets with varying essential/nonessential amino acid ratios on mouse lifespan</article-title><source>Nutrients</source><year>2019</year><volume>11</volume><elocation-id>1367</elocation-id><pub-id pub-id-type="doi">10.3390/nu11061367</pub-id><pub-id pub-id-type="pmid">31216646</pub-id><pub-id pub-id-type="pmcid">PMC6628056</pub-id></element-citation></ref><ref id="B111-nutrients-17-02813"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vlahakis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Graef</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nunnari</surname><given-names>J.</given-names></name><name name-style="western"><surname>Powers</surname><given-names>T.</given-names></name></person-group><article-title>TOR complex 2-Ypk1 signaling is an essential positive regulator of the general amino acid control response and autophagy</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>10586</fpage><lpage>10591</lpage><pub-id pub-id-type="doi">10.1073/pnas.1406305111</pub-id><pub-id pub-id-type="pmid">25002487</pub-id><pub-id pub-id-type="pmcid">PMC4115538</pub-id></element-citation></ref><ref id="B112-nutrients-17-02813"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corsetti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Flati</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pasini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sanit&#224;</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dioguardi</surname><given-names>F.S.</given-names></name></person-group><article-title>Protect and counterattack: Nutritional supplementation with essential amino acid ratios reduces doxorubicin&#8211;induced cardiotoxicity in vivo and promote cancer cell death in vitro</article-title><source>J. Cytol. Histol.</source><year>2015</year><volume>6</volume><fpage>5</fpage><pub-id pub-id-type="doi">10.4172/2157-7099.1000354</pub-id></element-citation></ref><ref id="B113-nutrients-17-02813"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corsetti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Romano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pasini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Scarabelli</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen-Scarabelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dioguardi</surname><given-names>F.S.</given-names></name></person-group><article-title>Essential amino acids-rich diet increases cardiomyocytes protection in doxorubicin-treated mice</article-title><source>Nutrients</source><year>2023</year><volume>15</volume><elocation-id>2287</elocation-id><pub-id pub-id-type="doi">10.3390/nu15102287</pub-id><pub-id pub-id-type="pmid">37242170</pub-id><pub-id pub-id-type="pmcid">PMC10222879</pub-id></element-citation></ref><ref id="B114-nutrients-17-02813"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;Antona</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ragni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cardile</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tedesco</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dossena</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bruttini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Caliaro</surname><given-names>F.</given-names></name><name name-style="western"><surname>Corsetti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bottinelli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Carruba</surname><given-names>M.O.</given-names></name><etal/></person-group><article-title>Branched-chain amino acid supplementation promotes survival and supports cardiac and skeletal muscle mitochondrial biogenesis in middle-aged mice</article-title><source>Cell Metab.</source><year>2010</year><volume>12</volume><fpage>362</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2010.08.016</pub-id><pub-id pub-id-type="pmid">20889128</pub-id></element-citation></ref><ref id="B115-nutrients-17-02813"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cools</surname><given-names>J.</given-names></name></person-group><article-title>Improvements in the survival of children and adolescents with acute lymphoblastic leukemia</article-title><source>Haematologica</source><year>2012</year><volume>97</volume><fpage>635</fpage><pub-id pub-id-type="doi">10.3324/haematol.2012.068361</pub-id><pub-id pub-id-type="pmid">22556350</pub-id><pub-id pub-id-type="pmcid">PMC3342961</pub-id></element-citation></ref><ref id="B116-nutrients-17-02813"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aldoss</surname><given-names>I.</given-names></name><name name-style="western"><surname>Douer</surname><given-names>D.</given-names></name></person-group><article-title>How I treat the toxicities of peg asparaginase in adults with acute lymphoblastic leukemia</article-title><source>Blood</source><year>2020</year><volume>135</volume><fpage>987</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1182/blood.2019002132</pub-id><pub-id pub-id-type="pmid">31977001</pub-id></element-citation></ref><ref id="B117-nutrients-17-02813"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandes</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Silva Teixeira</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Cerqueira</surname><given-names>N.M.</given-names></name></person-group><article-title>Amino acid deprivation using enzymes as a targeted therapy for cancer and viral infections</article-title><source>Expert. Opin. Ther. Pat.</source><year>2017</year><volume>27</volume><fpage>283</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1080/13543776.2017.1254194</pub-id><pub-id pub-id-type="pmid">27813440</pub-id></element-citation></ref><ref id="B118-nutrients-17-02813"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sanderson</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Richie</surname><given-names>J.P.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Ciccarella</surname><given-names>A.</given-names></name><name name-style="western"><surname>Calcagnotto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mikhael</surname><given-names>P.G.</given-names></name><etal/></person-group><article-title>Dietary methionine influences therapy in mouse cancer models and alters human metabolism</article-title><source>Nature</source><year>2019</year><volume>572</volume><fpage>397</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1437-3</pub-id><pub-id pub-id-type="pmid">31367041</pub-id><pub-id pub-id-type="pmcid">PMC6951023</pub-id></element-citation></ref><ref id="B119-nutrients-17-02813"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>DeBerardinis</surname><given-names>R.J.</given-names></name></person-group><article-title>Mechanisms and implications of metabolic heterogeneity in cancer</article-title><source>Cell Metab.</source><year>2019</year><volume>30</volume><fpage>434</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2019.08.013</pub-id><pub-id pub-id-type="pmid">31484055</pub-id><pub-id pub-id-type="pmcid">PMC6730674</pub-id></element-citation></ref><ref id="B120-nutrients-17-02813"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tajan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vousden</surname><given-names>K.H.</given-names></name></person-group><article-title>Dietary approaches to cancer therapy</article-title><source>Cancer Cell</source><year>2020</year><volume>37</volume><fpage>767</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2020.04.005</pub-id><pub-id pub-id-type="pmid">32413275</pub-id></element-citation></ref><ref id="B121-nutrients-17-02813"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>S.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moriwaki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Higuchi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nishiguchi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibit liver carcinogenesis in heavier patients with liver cirrhosis</article-title><source>Hepatol. Res.</source><year>2006</year><volume>35</volume><fpage>204</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.hepres.2006.04.007</pub-id><pub-id pub-id-type="pmid">16737844</pub-id></element-citation></ref><ref id="B122-nutrients-17-02813"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimizu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shirakami</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hanai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Imai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Suetsugu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Takai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shiraki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moriwaki</surname><given-names>H.</given-names></name></person-group><article-title>Pharmaceutical and nutraceutical approaches for preventing liver carcinogenesis: Chemoprevention of hepatocellular carcinoma using acyclic retinoid and branched-chain amino acids</article-title><source>Mol. Nutr. Food Res.</source><year>2014</year><volume>58</volume><fpage>124</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1002/mnfr.201300538</pub-id><pub-id pub-id-type="pmid">24273224</pub-id></element-citation></ref><ref id="B123-nutrients-17-02813"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mascaretti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Parpinel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Serraino</surname><given-names>D.</given-names></name><name name-style="western"><surname>Crispo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Celentano</surname><given-names>E.</given-names></name><name name-style="western"><surname>Giacosa</surname><given-names>A.</given-names></name><name name-style="western"><surname>La Vecchia</surname><given-names>C.</given-names></name></person-group><article-title>Dietary intake of branched-chain amino acids and colon rectal cancer risk</article-title><source>Br. J. Nutr.</source><year>2021</year><volume>126</volume><fpage>22</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1017/S0007114520003724</pub-id><pub-id pub-id-type="pmid">32962776</pub-id></element-citation></ref><ref id="B124-nutrients-17-02813"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayers</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Clish</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Kraft</surname><given-names>P.</given-names></name><name name-style="western"><surname>Torrence</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Fiske</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Townsend</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Tworoger</surname><given-names>S.S.</given-names></name><etal/></person-group><article-title>Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development</article-title><source>Nat. Med.</source><year>2014</year><volume>20</volume><fpage>1193</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1038/nm.3686</pub-id><pub-id pub-id-type="pmid">25261994</pub-id><pub-id pub-id-type="pmcid">PMC4191991</pub-id></element-citation></ref><ref id="B125-nutrients-17-02813"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katagiri</surname><given-names>R.</given-names></name><name name-style="western"><surname>Goto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nishiumi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hidaka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Budhathoki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yamaji</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sawada</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shimazu</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Increased levels of branched-chain amino acid associated with increased risk of pancreatic cancer in a prospective case-control study of a large cohort</article-title><source>Gastroenterology</source><year>2018</year><volume>155</volume><fpage>1474</fpage><lpage>1482</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2018.07.033</pub-id><pub-id pub-id-type="pmid">30076838</pub-id></element-citation></ref><ref id="B126-nutrients-17-02813"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sivanand</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vander Heiden</surname><given-names>M.G.</given-names></name></person-group><article-title>Emerging roles for branched-chain amino acid metabolism in cancer</article-title><source>Cancer Cell</source><year>2020</year><volume>37</volume><fpage>147</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2019.12.011</pub-id><pub-id pub-id-type="pmid">32049045</pub-id><pub-id pub-id-type="pmcid">PMC7082774</pub-id></element-citation></ref><ref id="B127-nutrients-17-02813"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagiwara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nishiyama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ishizaki</surname><given-names>S.</given-names></name></person-group><article-title>Branched-chain amino acids prevent insulin-induced hepatic tumor cell proliferation by inducing apoptosis through mTORC1 and mTORC2-dependent mechanisms</article-title><source>J. Cell Physiol.</source><year>2012</year><volume>227</volume><fpage>2097</fpage><lpage>2105</lpage><pub-id pub-id-type="doi">10.1002/jcp.22941</pub-id><pub-id pub-id-type="pmid">21769869</pub-id></element-citation></ref><ref id="B128-nutrients-17-02813"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dioguardi</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Chen-Scarabelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pasini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Corsetti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Scarabelli</surname><given-names>T.M.</given-names></name></person-group><article-title>Diet, muscle protein synthesis and autophagy relationships in cancer an attempt to understand where are we going, and why</article-title><source>Adv. Nutr. Food Sci.</source><year>2022</year><volume>2022</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.37722/ANAFS.2022401</pub-id></element-citation></ref><ref id="B129-nutrients-17-02813"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ciu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>General rules for treating cancer-related malnutrition</article-title><source>Precis. Nutr.</source><year>2022</year><volume>1</volume><fpage>e00024</fpage><pub-id pub-id-type="doi">10.1097/PN9.0000000000000024</pub-id></element-citation></ref><ref id="B130-nutrients-17-02813"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Birdsell</surname><given-names>L.</given-names></name><name name-style="western"><surname>Macdonald</surname><given-names>N.</given-names></name><name name-style="western"><surname>Reiman</surname><given-names>T.</given-names></name><name name-style="western"><surname>Clandinin</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>McCargar</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sawyer</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Baracos</surname><given-names>V.E.</given-names></name></person-group><article-title>Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index</article-title><source>J. Clin. Oncol.</source><year>2013</year><volume>31</volume><fpage>1539</fpage><lpage>1547</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.45.2722</pub-id><pub-id pub-id-type="pmid">23530101</pub-id></element-citation></ref><ref id="B131-nutrients-17-02813"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arends</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bachmann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Baracos</surname><given-names>V.</given-names></name><name name-style="western"><surname>Barthelemy</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bertz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bozzetti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fearon</surname><given-names>K.</given-names></name><name name-style="western"><surname>H&#252;tterer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Isenring</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kaasa</surname><given-names>S.</given-names></name><etal/></person-group><article-title>ESPEN guidelines on nutrition in cancer patients</article-title><source>Clin. Nutr.</source><year>2017</year><volume>36</volume><fpage>11</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2016.07.015</pub-id><pub-id pub-id-type="pmid">27637832</pub-id></element-citation></ref><ref id="B132-nutrients-17-02813"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arends</surname><given-names>J.</given-names></name></person-group><article-title>Malnutrition in cancer patients: Causes, consequences and treatment options</article-title><source>Eur. J. Surg. Oncol.</source><year>2024</year><volume>50</volume><fpage>107074</fpage><pub-id pub-id-type="doi">10.1016/j.ejso.2023.107074</pub-id><pub-id pub-id-type="pmid">37783594</pub-id></element-citation></ref><ref id="B133-nutrients-17-02813"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Felder</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gueissaz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bolliger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tribolet</surname><given-names>P.</given-names></name><name name-style="western"><surname>K&#228;gi-Braun</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hoess</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pavlicek</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bilz</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Association of baseline inflammation with effectiveness of nutritional support among patients with disease-related malnutrition: A secondary analysis of a randomized clinical trial</article-title><source>JAMA New Open</source><year>2020</year><volume>3</volume><fpage>e200663</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.0663</pub-id><pub-id pub-id-type="pmcid">PMC7064875</pub-id><pub-id pub-id-type="pmid">32154887</pub-id></element-citation></ref><ref id="B134-nutrients-17-02813"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laird</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Kaasa</surname><given-names>S.</given-names></name><name name-style="western"><surname>McMillan</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Fallon</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Hjermstad</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Fayers</surname><given-names>P.</given-names></name><name name-style="western"><surname>Klepstad</surname><given-names>P.</given-names></name></person-group><article-title>Prognostic factors in patients with advanced cancer: A comparison of clinicopathological factors and the development of an inflammation-based prognostic system</article-title><source>Clin. Cancer Res.</source><year>2013</year><volume>19</volume><fpage>5456</fpage><lpage>5464</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-1066</pub-id><pub-id pub-id-type="pmid">23938289</pub-id></element-citation></ref><ref id="B135-nutrients-17-02813"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Meij</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Teleni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Engelen</surname><given-names>M.P.K.J.</given-names></name><name name-style="western"><surname>Deutz</surname><given-names>N.E.P.</given-names></name></person-group><article-title>Amino acid kinetics and the response to nutrition in patients with cancer</article-title><source>Int. J. Radiat. Biol.</source><year>2019</year><volume>95</volume><fpage>480</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1080/09553002.2018.1466209</pub-id><pub-id pub-id-type="pmid">29667485</pub-id></element-citation></ref><ref id="B136-nutrients-17-02813"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brook</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Atherton</surname><given-names>P.J.</given-names></name></person-group><article-title>Nutrient modulation in the management of disease-induced muscle wasting: Evidence from human studies</article-title><source>Curr. Opin. Clin. Nutr. Metab. Care</source><year>2017</year><volume>20</volume><fpage>433</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1097/MCO.0000000000000413</pub-id><pub-id pub-id-type="pmid">28832372</pub-id></element-citation></ref><ref id="B137-nutrients-17-02813"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prado</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Purcell</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Laviano</surname><given-names>A.</given-names></name></person-group><article-title>Nutrition interventions to treat low muscle mass in cancer</article-title><source>J. Cachexia Sarcopenia Muscle</source><year>2020</year><volume>11</volume><fpage>366</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1002/jcsm.12525</pub-id><pub-id pub-id-type="pmid">31916411</pub-id><pub-id pub-id-type="pmcid">PMC7113510</pub-id></element-citation></ref><ref id="B138-nutrients-17-02813"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beaudry</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Law</surname><given-names>M.L.</given-names></name></person-group><article-title>Leucine supplementation in cancer cachexia: Mechanisms and a review of the pre-clinical literature</article-title><source>Nutrients</source><year>2022</year><volume>14</volume><elocation-id>2824</elocation-id><pub-id pub-id-type="doi">10.3390/nu14142824</pub-id><pub-id pub-id-type="pmid">35889781</pub-id><pub-id pub-id-type="pmcid">PMC9323748</pub-id></element-citation></ref><ref id="B139-nutrients-17-02813"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salom&#227;o</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Toneto</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>G.O.</given-names></name><name name-style="western"><surname>Gomes-Marcondes</surname><given-names>M.C.C.</given-names></name></person-group><article-title>Physical exercise and a leucine-rich diet modulate the muscle protein metabolism in walker tumor-bearing rats</article-title><source>Nut. Cancer</source><year>2010</year><volume>62</volume><fpage>1095</fpage><lpage>1104</lpage><pub-id pub-id-type="doi">10.1080/01635581.2010.492082</pub-id><pub-id pub-id-type="pmid">21058197</pub-id></element-citation></ref><ref id="B140-nutrients-17-02813"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aquilani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dioguardi</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>D&#8217;Antona</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gheorghiade</surname><given-names>M.</given-names></name><name name-style="western"><surname>Taegtmeyer</surname><given-names>H.</given-names></name></person-group><article-title>Hypercatabolic syndrome: Molecular basis and effects of nutritional supplements with amino acids</article-title><source>Am. J. Cardiol.</source><year>2008</year><volume>101</volume><fpage>11E</fpage><lpage>15E</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2008.02.074</pub-id><pub-id pub-id-type="pmid">18514619</pub-id></element-citation></ref><ref id="B141-nutrients-17-02813"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aquilani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zuccarelli Ginetto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rutili</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pisano</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pasini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Baldissarro</surname><given-names>E.</given-names></name><name name-style="western"><surname>Verri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Boschi</surname><given-names>F.</given-names></name></person-group><article-title>Supplemented amino acids may enhance the walking recovery of elderly subjects after hip fracture surgery</article-title><source>Aging Clin. Exp. Res.</source><year>2019</year><volume>31</volume><fpage>157</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1007/s40520-018-0941-x</pub-id><pub-id pub-id-type="pmid">29667153</pub-id></element-citation></ref><ref id="B142-nutrients-17-02813"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dal Negro</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Aquilani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bertacco</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boschi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Micheletto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tognella</surname><given-names>S.</given-names></name></person-group><article-title>Comprehensive effects of supplemented essential amino acids in patients with severe COPD and sarcopenia</article-title><source>Monaldi Arch. Chest Dis.</source><year>2010</year><volume>73</volume><fpage>25</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.4081/monaldi.2010.310</pub-id><pub-id pub-id-type="pmid">20499791</pub-id></element-citation></ref><ref id="B143-nutrients-17-02813"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buondonno</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sassi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Carignano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dutto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ferreri</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pili</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Massaia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nisoli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ruocco</surname><given-names>C.</given-names></name><name name-style="western"><surname>Porrino</surname><given-names>P.</given-names></name><etal/></person-group><article-title>From mitochondria to healthy aging: The role of branched-chain amino acids treatment: MATeR a randomized study</article-title><source>Clin. Nutr.</source><year>2020</year><volume>39</volume><fpage>2080</fpage><lpage>2091</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2019.10.013</pub-id><pub-id pub-id-type="pmid">31672329</pub-id></element-citation></ref><ref id="B144-nutrients-17-02813"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steck</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>E.A.</given-names></name></person-group><article-title>Dietary patterns and cancer risk</article-title><source>Nat. Rev. Cancer</source><year>2020</year><volume>20</volume><fpage>125</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1038/s41568-019-0227-4</pub-id><pub-id pub-id-type="pmid">31848467</pub-id></element-citation></ref><ref id="B145-nutrients-17-02813"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flati</surname><given-names>V.</given-names></name><name name-style="western"><surname>Caliaro</surname><given-names>F.</given-names></name><name name-style="western"><surname>Speca</surname><given-names>S.</given-names></name><name name-style="western"><surname>Corsetti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cardile</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nisoli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bottinelli</surname><given-names>R.</given-names></name><name name-style="western"><surname>D&#8217;Antona</surname><given-names>G.</given-names></name></person-group><article-title>Essential amino acids improveinsulin activation of AKT/MTOR signaling in soleus muscle of agedrats</article-title><source>Int. J. Immunopathol. Pharmacol.</source><year>2010</year><volume>23</volume><fpage>81</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1177/039463201002300108</pub-id><pub-id pub-id-type="pmid">20377997</pub-id></element-citation></ref><ref id="B146-nutrients-17-02813"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madeddu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Macci&#242;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Astara</surname><given-names>G.</given-names></name><name name-style="western"><surname>Massa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dess&#236;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Antoni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Panzone</surname><given-names>F.</given-names></name><name name-style="western"><surname>Serpe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mantovan</surname><given-names>G.</given-names></name></person-group><article-title>Open phase II study on efficacy and safety of an oral amino acid functional cluster supplementation in cancer cachexia</article-title><source>Med. J. Nutr. Metab.</source><year>2010</year><volume>3</volume><fpage>165</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1007/s12349-010-0016-9</pub-id></element-citation></ref><ref id="B147-nutrients-17-02813"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Layman</surname><given-names>D.K.</given-names></name></person-group><article-title>Dietary Guidelines should reflect new understandings about adult protein needs</article-title><source>Nutr. Metab.</source><year>2009</year><volume>6</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/1743-7075-6-12</pub-id><pub-id pub-id-type="pmcid">PMC2666737</pub-id><pub-id pub-id-type="pmid">19284668</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="nutrients-17-02813-f001" orientation="portrait"><label>Figure 1</label><caption><p>Schematic representation of the dual effects of leucine on tumor progression.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-17-02813-g001.jpg"/></fig><fig position="float" id="nutrients-17-02813-f002" orientation="portrait"><label>Figure 2</label><caption><p>Schematic summary of opposing outcomes driven by excess non-essential (NEAAs) versus essential amino acids (EAAs) in cancer and healthy cells. NEAAs promote tumor progression through metabolic support and tumor microenvironment (TME, delimited by the dotted line) remodeling, whereas EAAs induce selective cancer cell death while preserving and enhancing normal cell viability and function. ME = microenvironment. ER = endoplasmic reticulum. TCA = tricarboxylic acid cycle. ATP = Adenosine triphosphate. ROS = Reactive oxygen species. SOD = Super oxide dismutase. mTOR = mammalian target of rapamycin. Immune cells: T = T-lymphocytes, NK = Natural-killer-lymphocytes. Arrow yellow: up = increase, down = decrease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-17-02813-g002.jpg"/></fig><fig position="float" id="nutrients-17-02813-f003" orientation="portrait"><label>Figure 3</label><caption><p>Schematic representation of the link between EAAs availability, ATP production, and mTOR activation. ATP, ADP, AMP = adenosine tri-, di-, and monophosphate. AMPK = AMP-activated protein kinase. mTORC1 = mammalian target of rapamycin subunit 1. The blue arrows indicated the anabolic pathway, the red ones the catabolic pathway. Black arrow up = increase. Black arrow down = decrease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-17-02813-g003.jpg"/></fig></floats-group></article></pmc-articleset>